Pictilisib (GDC-0941)

Name: Pictilisib (GDC-0941)
Brand: Selleck Chemicals
SKU: S1065
Rating: 5 (335 reviews)

For research use only.

Catalog No.S1065 Synonyms: RG7321

335 publications

Pictilisib (GDC-0941) Chemical Structure

CAS No. 957054-30-7

Pictilisib (GDC-0941, RG7321) is a potent inhibitor of PI3Kα/δ with IC50 of 3 nM in cell-free assays, with modest selectivity against p110β (11-fold) and p110γ (25-fold). Pictilisib (GDC-0941) induces autophagy and apoptosis. Phase 2.

Selleck's Pictilisib (GDC-0941) has been cited by 335 publications

Cell, 2020, 182(3):685-712.e19

PubMed: 32645325 ( click the link to review the publication )

Nat Med, 2019, 25(5):838-849

PubMed: 31011202 ( click the link to review the publication )

Nat Med, 2018, 24(7):968-977

PubMed: 29808010 ( click the link to review the publication )

Nat Med, 2018, 24(7):954-960

PubMed: 29808009 ( click the link to review the publication )

Cell, 2018, 172(1-2):373-386

PubMed: 29224780 ( click the link to review the publication )

Nat Med, 2017, 23(11):1342-1351

PubMed: 29035366 ( click the link to review the publication )

J Clin Oncol, 2016, 34(8):794-802

PubMed: 26215952 ( click the link to review the publication )

Cancer Discov, 2016, 6(8):838-851

PubMed: 27179038 ( click the link to review the publication )

Nat Med, 2015, 21(9):1038-47

PubMed: 26301689 ( click the link to review the publication )

Cancer Discov, 2015, 5(3):264-73

PubMed: 25542447 ( click the link to review the publication )

Nature, 2014, 3;508(7494):118-22.

PubMed: 24670642 ( click the link to review the publication )

Cancer Discov, 2014, 4(1):94-109

PubMed: 24265153 ( click the link to review the publication )

Cell, 2013, 7;155(4):844-57.

PubMed: 24209622 ( click the link to review the publication )

Cancer Discov, 2012, 2(11):1036-47

PubMed: 22915752 ( click the link to review the publication )

Cell Stem Cell, 2012, 10(2):210-7

PubMed: 22305570 ( click the link to review the publication )

Cancer Discov, 2011, 1(7):608-25

PubMed: 22586683 ( click the link to review the publication )

Oncogenesis, 2021, 10(1):8

PubMed: 33431808 ( click the link to review the publication )

Food Chem Toxicol, 2021, S0278-6915(21)00034-X

PubMed: 33484789 ( click the link to review the publication )

Nat Cell Biol, 2020, 22(3):289-296

PubMed: 32094692 ( click the link to review the publication )

Mol Cell, 2020, 80(1):164-174.e4

PubMed: 32877642 ( click the link to review the publication )

Nat Microbiol, 2020, 10.1038/s41564-020-0782-1

PubMed: 32895527 ( click the link to review the publication )

Nat Commun, 2020, 8;11(1):2291

PubMed: 32385243 ( click the link to review the publication )

Nat Commun, 2020, 11(1):1290

PubMed: 32157087 ( click the link to review the publication )

Sci Adv, 2020, 6(34):eaba8968

PubMed: 32937365 ( click the link to review the publication )
EMBO Mol Med, 2020, e11674

PubMed: 32558386 ( click the link to review the publication )

EMBO Mol Med, 2020, 12(8):e11987

PubMed: 32672423 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2020, 117(39):24427-24433

PubMed: 32929011 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2020, 117(49):31189-31197

PubMed: 33229547 ( click the link to review the publication )

Cell Syst, 2020, 20;10(5):384-396.e9

PubMed: 32437683 ( click the link to review the publication )

Cell Syst, 2020, 10(3):240-253

PubMed: 32191874 ( click the link to review the publication )

Cell Rep, 2020, 31(12):107800

PubMed: 32579927 ( click the link to review the publication )

Cell Rep, 2020, 30(13):4584-4599

PubMed: 32234489 ( click the link to review the publication )

J Control Release, 2020, 318:98-108

PubMed: 31838203 ( click the link to review the publication )

Sci Signal, 2020, 13(637):eaba8627

PubMed: 32576681 ( click the link to review the publication )

Cancers (Basel), 2020, 12(11)E3172

PubMed: 33126775 ( click the link to review the publication )

Cell Death Dis, 2020, 11(9):765

PubMed: 32943605 ( click the link to review the publication )

Br J Cancer, 2020, 22

PubMed: 32439932 ( click the link to review the publication )

Br J Cancer, 2020, 10.1038/s41416-020-0952-1

PubMed: 32572172 ( click the link to review the publication )

Mol Cancer Ther, 2020, 5;molcanther.1131.2019

PubMed: 32371585 ( click the link to review the publication )

Mol Oncol, 2020, 26

PubMed: 32336009 ( click the link to review the publication )

Cell Oncol (Dordr), 2020, 8

PubMed: 32382996 ( click the link to review the publication )

Front Oncol, 2020, 1;10:393

PubMed: 32296637 ( click the link to review the publication )

Sci Rep, 2020, 4;10(1):7401

PubMed: 32366879 ( click the link to review the publication )

Sci Rep, 2020, 10(1):218

PubMed: 31937834 ( click the link to review the publication )

Am J Physiol Cell Physiol, 2020, 10.1152/ajpcell.00290.2020

PubMed: 32966125 ( click the link to review the publication )

Eur J Pharmacol, 2020, 873:172981

PubMed: 32014486 ( click the link to review the publication )

Oncol Lett, 2020, 20(1):533-540

PubMed: 32565979 ( click the link to review the publication )

J Cell Biol, 2020, 219(2)

PubMed: 31914171 ( click the link to review the publication )
JCI Insight, 2020, 5(22)141832

PubMed: 33048843 ( click the link to review the publication )

Oncotarget, 2020, 28;11(17):1493-1504

PubMed: 32391119 ( click the link to review the publication )

STAR Protoc, 2020, 1(1)100016

PubMed: 32984851 ( click the link to review the publication )

Blood Adv, 2020, 4(18):4382-4392

PubMed: 32926124 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2532

PubMed: 31182717 ( click the link to review the publication )

J Clin Invest, 2019, 129(12):5584-5599

PubMed: 31527310 ( click the link to review the publication )

Nat Commun, 2019, 10(1):1473

PubMed: 30931927 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432

PubMed: 31227503 ( click the link to review the publication )

Cancer Res, 2019, 79(6):1138-1150

PubMed: 30679179 ( click the link to review the publication )

Haematologica, 2019, 104(11):2225-2240

PubMed: 30819918 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(9):2835-2847

PubMed: 30670492 ( click the link to review the publication )

Cancer Res, 2019, 79(11):2892-2908

PubMed: 31048499 ( click the link to review the publication )

Cell Rep, 2019, 27(1):294-306

PubMed: 30943409 ( click the link to review the publication )

Cell Rep, 2019, 27(2):631-647

PubMed: 30970263 ( click the link to review the publication )

Cell Rep, 2019, 28(9):2317-2330

PubMed: 31461649 ( click the link to review the publication )

Haematologica, 2019, 10.3324/haematol.2019.216218

PubMed: 31471373 ( click the link to review the publication )

Int J Cancer, 2019, 145(3):817-829

PubMed: 30671946 ( click the link to review the publication )

Oncogene, 2019, 38(15):2690-2705

PubMed: 30538293 ( click the link to review the publication )

Br J Pharmacol, 2019, 176(3):436-450

PubMed: 30427531 ( click the link to review the publication )

MBio, 2019, 10(1)

PubMed: 30755508 ( click the link to review the publication )

Cancer Lett, 2019, 466:23-34

PubMed: 31521695 ( click the link to review the publication )

J Invest Dermatol, 2019, 139(9):2004-2015

PubMed: 31059696 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):41

PubMed: 30691487 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):236

PubMed: 31164152 ( click the link to review the publication )
Cells, 2019, 8(2)

PubMed: 30795621 ( click the link to review the publication )

Mol Cancer Res, 2019, 10.1158/1541-7786.MCR-18-1332

PubMed: 31043489 ( click the link to review the publication )

Mol Cancer Res, 2019, 17(12):2395-2409

PubMed: 31548239 ( click the link to review the publication )

J Cell Mol Med, 2019, 23(2):920-933

PubMed: 30394679 ( click the link to review the publication )

J Transl Med, 2019, 17(1):431

PubMed: 31888636 ( click the link to review the publication )

Sci Rep, 2019, 9(1):1897

PubMed: 30760778 ( click the link to review the publication )

Sci Rep, 2019,

PubMed: 31882967 ( click the link to review the publication )

Front Microbiol, 2019,

PubMed: 32038504 ( click the link to review the publication )

Acta Pharmacol Sin, 2019, 40(5):677-688

PubMed: 30224636 ( click the link to review the publication )

Cancer Manag Res, 2019, 11:839-855

PubMed: 30697076 ( click the link to review the publication )

Int J Oncol, 2019, 54(2):431-442

PubMed: 30483742 ( click the link to review the publication )

Invest Ophthalmol Vis Sci, 2019, 60(7):2764-2772

PubMed: 31247083 ( click the link to review the publication )

Int J Mol Med, 2019, 44(5):1789-1800

PubMed: 31545402 ( click the link to review the publication )

Pestic Biochem Physiol, 2019, 154:67-77

PubMed: 30765058 ( click the link to review the publication )

Contrast Media Mol Imaging, 2019, 2019:1760184

PubMed: 31787861 ( click the link to review the publication )

Life Sci Alliance, 2019, 2(6)

PubMed: 31704709 ( click the link to review the publication )

Cancer Biol Med, 2019, 16(1):66-83

PubMed: 31119047 ( click the link to review the publication )

Nat Biomed Eng, 2018, 2(8):578-588

PubMed: 31015631 ( click the link to review the publication )

Blood, 2018, 10.1182/blood-2018-08-872465

PubMed: 30322870 ( click the link to review the publication )

Mol Cell, 2018, 71(6):1092-1104

PubMed: 30174291 ( click the link to review the publication )

Nat Chem Biol, 2018, 14(8):768-777

PubMed: 29942081 ( click the link to review the publication )

J Clin Invest, 2018, 128(1):446-462

PubMed: 29202477 ( click the link to review the publication )

Nat Commun, 2018, 9(1):4945

PubMed: 30470748 ( click the link to review the publication )

Nat Commun, 2018, 9(1):2434

PubMed: 29934552 ( click the link to review the publication )
Genes Dev, 2018, 32(17-18):1201-1214

PubMed: 30143526 ( click the link to review the publication )

Cancer Res, 2018, 78(13):3645-3658

PubMed: 29760043 ( click the link to review the publication )

NPJ Genom Med, 2018, 3:15

PubMed: 29951225 ( click the link to review the publication )

Clin Cancer Res, 2018, 15;24(6):1436-1447

PubMed: 29127119 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(23):6066-6077

PubMed: 30061362 ( click the link to review the publication )

J Cell Biol, 2018, 217(5):1701-1717

PubMed: 29545370 ( click the link to review the publication )

Cancer Res, 2018, 78(15):4396-4410

PubMed: 29844118 ( click the link to review the publication )

Cell Rep, 2018, 22(4):860-868

PubMed: 29420173 ( click the link to review the publication )

Oncogene, 2018, 37(10):1369-1385

PubMed: 29311642 ( click the link to review the publication )

Cancer Lett, 2018, 439:56-65

PubMed: 30243708 ( click the link to review the publication )

J Invest Dermatol, 2018, 138(11):2377-2387

PubMed: 29758280 ( click the link to review the publication )

EBioMedicine, 2018, 28:80-89

PubMed: 29396295 ( click the link to review the publication )

Cancers (Basel), 2018, 10(12)

PubMed: 30545064 ( click the link to review the publication )

Cell Death Dis, 2018, 9(8):809

PubMed: 30042442 ( click the link to review the publication )

Bioinformatics, 2018, 34(17):i997-i1004

PubMed: 30423075 ( click the link to review the publication )

Bioinformatics, 2018, 34(23):4079-4086

PubMed: 29931053 ( click the link to review the publication )

Oncogenesis, 2018, 7(9):71

PubMed: 30237393 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(3):543-553

PubMed: 29222171 ( click the link to review the publication )

J Am Heart Assoc, 2018, 7(6)

PubMed: 29514810 ( click the link to review the publication )

Am J Physiol Lung Cell Mol Physiol, 2018, 315(6):L965-L976

PubMed: 30211651 ( click the link to review the publication )

Am J Respir Cell Mol Biol, 2018, 58(2):181-193

PubMed: 28915060 ( click the link to review the publication )

Int J Oncol, 2018, 52(3):828-840

PubMed: 29344641 ( click the link to review the publication )

Int J Oncol, 2018, 53(5):1881-1896

PubMed: 30132519 ( click the link to review the publication )

Proteomics, 2018, 18(23):e1800244

PubMed: 30267477 ( click the link to review the publication )
Invest New Drugs, 2018, 36(5):763-772

PubMed: 29504069 ( click the link to review the publication )

Cell Signal, 2018, 44:127-137

PubMed: 29329780 ( click the link to review the publication )

Prostate, 2018, 78(13):1013-1023

PubMed: 30133757 ( click the link to review the publication )

Oncol Rep, 2018, 40(2):715-725

PubMed: 29901201 ( click the link to review the publication )

PLoS One, 2018, 13(5):e0193849

PubMed: 29799846 ( click the link to review the publication )

PLoS One, 2018, 13(8):e0200725

PubMed: 30067771 ( click the link to review the publication )

Anticancer Res, 2018, 38(11):6195-6200

PubMed: 30396937 ( click the link to review the publication )

JCI Insight, 2018, 3(4)

PubMed: 29467326 ( click the link to review the publication )

Cell Host Microbe, 2017, 21(5):611-618

PubMed: 28494242 ( click the link to review the publication )

Mol Cell, 2017, 67(3):512-527

PubMed: 28757207 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1090

PubMed: 29061961 ( click the link to review the publication )

Nat Commun, 2017, 8:13897

PubMed: 28059068 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1278

PubMed: 29097657 ( click the link to review the publication )

Nat Commun, 2017, 8(1):2249

PubMed: 29269732 ( click the link to review the publication )

Nucleic Acids Res, 2017, 45(16):9654-9678

PubMed: 28934469 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(18):5561-5572

PubMed: 28606920 ( click the link to review the publication )

Cancer Res, 2017, 77(15):4135-4145

PubMed: 28615225 ( click the link to review the publication )

Cancer Res, 2017, 77(8):1892-1904

PubMed: 28108509 ( click the link to review the publication )

J Cell Biol, 2017, 216(6):1567-1577

PubMed: 28442534 ( click the link to review the publication )

Theranostics, 2017, 7(4):974-986

PubMed: 28382169 ( click the link to review the publication )

Mol Syst Biol, 2017, 13(1):905

PubMed: 28069687 ( click the link to review the publication )

Oncogene, 2017, 36(41):5681-5694

PubMed: 28604746 ( click the link to review the publication )

Oncogene, 2017, 36(36):5110-5121

PubMed: 28481878 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(2):285-299

PubMed: 27980108 ( click the link to review the publication )
Mol Cancer Ther, 2017, 10.1158/1535-7163.MCT-16-0415

PubMed: 28119489 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(6):1054-1067

PubMed: 28336808 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(10):2130-2143

PubMed: 28751539 ( click the link to review the publication )

Oncogenesis, 2017, 6(11):398

PubMed: 29184057 ( click the link to review the publication )

Cell Discov, 2017, 3:16054

PubMed: 28224045 ( click the link to review the publication )

Mol Pharm, 2017, 14(7):2368-2377

PubMed: 28597653 ( click the link to review the publication )

J Immunol, 2017, 198(2):657-668

PubMed: 27940659 ( click the link to review the publication )

Sci Rep, 2017, 7(1):5519

PubMed: 28717217 ( click the link to review the publication )

Sci Rep, 2017, 7(1):3964

PubMed: 28638122 ( click the link to review the publication )

Mol Pharmacol, 2017, 91(1):65-73

PubMed: 27821547 ( click the link to review the publication )

Cancer Biol Ther, 2017, 18(10):816-826

PubMed: 29099264 ( click the link to review the publication )

Biol Reprod, 2017, 97(5):671-687

PubMed: 29036279 ( click the link to review the publication )

PLoS One, 2017, 12(7):e0181243

PubMed: 28704514 ( click the link to review the publication )

Am J Reprod Immunol, 2017, 78(4)

PubMed: 28635072 ( click the link to review the publication )

Curr Cancer Drug Targets, 2017, 17(8):722-734

PubMed: 28359246 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 489(1):14-20

PubMed: 28536078 ( click the link to review the publication )

SLAS Discov, 2017, 22(5):507-515

PubMed: 28324660 ( click the link to review the publication )

Oncotarget, 2017, 8(3):5349-5360

PubMed: 28029662 ( click the link to review the publication )

Oncotarget, 2017, 8(5):7878-7890

PubMed: 28002802 ( click the link to review the publication )

Oncotarget, 2017, 8(3):4277-4288

PubMed: 28032592 ( click the link to review the publication )

Oncotarget, 2017, 8(4):6608-6622

PubMed: 28036259 ( click the link to review the publication )

Oncotarget, 2017, 8(2):3259-3273

PubMed: 27965462 ( click the link to review the publication )

Oncotarget, 2017, 8(26):42343-42358

PubMed: 28418845 ( click the link to review the publication )

Oncotarget, 2017, 8(11):17995-18009

PubMed: 28152508 ( click the link to review the publication )
Physiol Rep, 2017, 5(18)e13441

PubMed: 28947594 ( click the link to review the publication )

Oncotarget, 2017, 8(3):5349-5360

PubMed: 28029662 ( click the link to review the publication )

Oncotarget, 2017, 8(32):52877-52888

PubMed: 28881779 ( click the link to review the publication )

Oncotarget, 2017, 8(8):12558-12575

PubMed: 28147342 ( click the link to review the publication )

Oncotarget, 2017, 8(26):42343-42358

PubMed: 28418845 ( click the link to review the publication )

Oncotarget, 2017, 8(38):63901-63910

PubMed: 28969039 ( click the link to review the publication )

Physiol Rep, 2017, 5(18)

PubMed: 28947594 ( click the link to review the publication )

Oncotarget, 2017, 8(47):83052-83062

PubMed: 29137323 ( click the link to review the publication )

Oncotarget, 2017, 9(10):8870-8886

PubMed: 29507660 ( click the link to review the publication )

Nat Commun, 2016, 7:13567

PubMed: 27876799 ( click the link to review the publication )

Nat Commun, 2016, 7:13650

PubMed: 27897192 ( click the link to review the publication )

J Thorac Oncol, 2016, 11(8):1345-1356

PubMed: 27117832 ( click the link to review the publication )

Leukemia, 2016, 30(9):1832-43

PubMed: 27174491 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2016, 113(6):1624-9

PubMed: 26811457 ( click the link to review the publication )

Cell Rep, 2016,

PubMed: 27292631 ( click the link to review the publication )

Elife, 2016, 5

PubMed: 27700986 ( click the link to review the publication )

Elife, 2016, 10.7554/eLife.18489

PubMed: 27845624 ( click the link to review the publication )

Oncogene, 2016, 35(27):3587-97

PubMed: 26549034 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2016, 29(3):317-28

PubMed: 26850518 ( click the link to review the publication )

Cancer Discov, 2016, 6(8):838-851

PubMed: 27179038 ( click the link to review the publication )

Cancer Discov, 2016, 6(10):1134-1147

PubMed: 27604488 ( click the link to review the publication )

Development, 2016, 143(23):4368-4380

PubMed: 27660325 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(7):1545-56

PubMed: 27196766 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(6):1248-60

PubMed: 27197306 ( click the link to review the publication )
Mol Cancer Ther, 2016, 15(1):94-105

PubMed: 26637365 ( click the link to review the publication )

Mol Cancer Ther, 2016,

PubMed: 27196766 ( click the link to review the publication )

Aging (Albany NY), 2016, 8(12):3507-3519

PubMed: 27992857 ( click the link to review the publication )

Mol Pharm, 2016, 13(11):3724-3735

PubMed: 27653969 ( click the link to review the publication )

Sci Rep, 2016, 6:37213

PubMed: 27849011 ( click the link to review the publication )

PLoS Comput Biol, 2016, 12(4):e1004827

PubMed: 27035903 ( click the link to review the publication )

PLoS One, 2016, 11(5):e0155230

PubMed: 27153109 ( click the link to review the publication )

Oncotarget, 2016, 7(15):19575-88

PubMed: 26988909 ( click the link to review the publication )

Oncotarget, 2016, 7(28):44448-44461

PubMed: 27286446 ( click the link to review the publication )

Oncotarget, 2016, 7(28):43124-43149

PubMed: 27281609 ( click the link to review the publication )

Oncotarget, 2016, 7(36):57525-57544

PubMed: 27438153 ( click the link to review the publication )

Oncotarget, 2016, 7(44):71211-71222

PubMed: 27655717 ( click the link to review the publication )

Oncotarget, 2016, 7(8):9188-221

PubMed: 26802026 ( click the link to review the publication )

Oncotarget, 2016, 7(50):82424-82439

PubMed: 27489350 ( click the link to review the publication )

Nat Commun, 2015, 6:7212

PubMed: 25998442 ( click the link to review the publication )

Nat Commun, 2015, 6:7935

PubMed: 26228240 ( click the link to review the publication )

Nat Commun, 2015, 6:8501

PubMed: 26442967 ( click the link to review the publication )

J Exp Med, 2015, 212(6):883-92

PubMed: 25987726 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2015, 112(28):8638-43

PubMed: 26124089 ( click the link to review the publication )

Mol Syst Biol, 2015, 11(3):797

PubMed: 25814555 ( click the link to review the publication )

Elife, 2015, 4:e10510

PubMed: 26523394 ( click the link to review the publication )

Elife, 2015, 4

PubMed: 25686219 ( click the link to review the publication )

Int J Cancer, 2015, 10.1002/ijc.29579

PubMed: 25912635 ( click the link to review the publication )

J Invest Dermatol, 2015, 135(12):3115-3124

PubMed: 26302068 ( click the link to review the publication )
Sci Signal, 2015, 8(401):ra111

PubMed: 26535009 ( click the link to review the publication )

Sci Signal, 2015, 8(396):ra96

PubMed: 26420907 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2015, 28(5):572-89

PubMed: 26112748 ( click the link to review the publication )

Cell Death Dis, 2015, 6:e1591

PubMed: 25590801 ( click the link to review the publication )

Cell Death Dis, 2015, 6:e1711

PubMed: 25837487 ( click the link to review the publication )

Exp Mol Med, 2015, 47:e143

PubMed: 25721419 ( click the link to review the publication )

Cell Commun Signal, 2015, 13:26

PubMed: 25975820 ( click the link to review the publication )

Neoplasia, 2015, 17(8):625-33

PubMed: 26408255 ( click the link to review the publication )

Hum Mol Genet, 2015, 24(4):926-38

PubMed: 25292196 ( click the link to review the publication )

Sci Rep, 2015, 5:14739

PubMed: 26446703 ( click the link to review the publication )

J Biol Chem, 2015, 290(35):21705-12

PubMed: 26152725 ( click the link to review the publication )

J Biol Chem, 2015, 290(40):24367-80

PubMed: 26294766 ( click the link to review the publication )

Proteomics, 2015, 15(2-3):327-39

PubMed: 25339196 ( click the link to review the publication )

Cancer Biol Ther, 2015, 16(3):402-11

PubMed: 25692408 ( click the link to review the publication )

Prostate, 2015, 75(3):242-54

PubMed: 25327687 ( click the link to review the publication )

Prostate, 2015, 75(3):242-54

PubMed: ( click the link to review the publication )

Cell Cycle, 2015, 14(4):648-55

PubMed: 25590338 ( click the link to review the publication )

PLoS One, 2015, 10(11):e0143357

PubMed: 26580203 ( click the link to review the publication )

PLoS One, 2015, 10(4):e0122689

PubMed: 25837824 ( click the link to review the publication )

PLoS One, 2015, 10(9):e0133610

PubMed: 26402468 ( click the link to review the publication )

PLoS One, 2015, 10(7):e0131400

PubMed: 26148118 ( click the link to review the publication )

Oncotarget, 2015, 6(11):9189-205

PubMed: 25826077 ( click the link to review the publication )

Oncotarget, 2015, 6(39):41976-87

PubMed: 26506516 ( click the link to review the publication )

Oncotarget, 2015, 6(7):5118-33

PubMed: 25742786 ( click the link to review the publication )
Oncotarget, 2015, 6(11):8722-35

PubMed: 25749378 ( click the link to review the publication )

Crit Rev Oncol Hematol, 2015, 96(3):507-17

PubMed: 26253360 ( click the link to review the publication )

Oncotarget, 2015, 6(41):43540-56

PubMed: 26498353 ( click the link to review the publication )

Oncotarget, 2015, 6(31):32089-103

PubMed: 26392332 ( click the link to review the publication )

Oncotarget, 2015, 6(22):18921-32

PubMed: 26254279 ( click the link to review the publication )

Oncotarget, 2015, 6(18):16488-506

PubMed: 26029997 ( click the link to review the publication )

Oncotarget, 2015, 6(32):33091-105

PubMed: 26384305 ( click the link to review the publication )

Oncotarget, 2015, 6(18):15814-27

PubMed: 26158412 ( click the link to review the publication )

Oncotarget, 2015, 6(31):31792-804

PubMed: 26397139 ( click the link to review the publication )

Oncotarget, 2015, 6(39):41976-87

PubMed: 26506516 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 26384305 ( click the link to review the publication )

Nat Struct Mol Biol, 2014, 21(6):522-7

PubMed: 24814346 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2014, 111(47):16826-9

PubMed: 25385636 ( click the link to review the publication )

Cancer Res, 2014, 10.1158/0008-5472.CAN-14-1392

PubMed: 25297634 ( click the link to review the publication )

Cancer Res, 2014, 74(17):4597-4611

PubMed: 25183785 ( click the link to review the publication )

Oncogene, 2014, 33(26):3422-31

PubMed: 23912457 ( click the link to review the publication )

Oncogene, 2014, 33(8):966-76

PubMed: 23474757 ( click the link to review the publication )

Oncogene, 2014, 33(35):4418-23

PubMed: 24469055 ( click the link to review the publication )

Oncogene, 2014, 10.1038/onc.2014.328

PubMed: 25284585 ( click the link to review the publication )

Oncogene, 2014, 33(23):3043-53

PubMed: 23893244 ( click the link to review the publication )

Breast Cancer Res, 2014, 16(4):406

PubMed: 25103565 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2014, 27(6):1154-8

PubMed: 25130256 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1134

PubMed: 24651437 ( click the link to review the publication )

Pain, 2014, 155(6):1150-60

PubMed: 24631588 ( click the link to review the publication )
Gastric Cancer, 2014, 10.1007/s10120-014-0444-1

PubMed: 25407459 ( click the link to review the publication )

Neoplasia, 2014, 16(2):147-57

PubMed: 24709422 ( click the link to review the publication )

Epigenetics, 2014, 9(4):611-20

PubMed: 24496381 ( click the link to review the publication )

Am J Cancer Res, 2014, 4(6):824-37

PubMed: 25520871 ( click the link to review the publication )

J Immunol, 2014, 193(6):3036-44

PubMed: 25092892 ( click the link to review the publication )

J Biol Chem, 2014, 289(33):22785-97

PubMed: 24982421 ( click the link to review the publication )

PLoS One, 2014, 9(11):e112148

PubMed: 25386922 ( click the link to review the publication )

PLoS One, 2014, 9(9):e105919

PubMed: 25221930 ( click the link to review the publication )

PLoS One, 2014, 9(1):e84746

PubMed: 24404189 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 10.1016/j.bbrc.2014.09.129

PubMed: 25285632 ( click the link to review the publication )

Mol Med Rep, 2014, 9(1):83-90

PubMed: 24213221 ( click the link to review the publication )

Anticancer Drugs, 2014, 25(2):183-8

PubMed: 24100276 ( click the link to review the publication )

Oncotarget, 2014, 5(16):7081-92

PubMed: 25216524 ( click the link to review the publication )

Oncotarget, 2014, 5(17):7328-41

PubMed: 25193862 ( click the link to review the publication )

Oncotarget, 2014, 5(13):5040-53

PubMed: 24970815 ( click the link to review the publication )

Oncotarget, 2014, 5(17):7936-44

PubMed: 25277205 ( click the link to review the publication )

Oncotarget, 2014, 5(18):8737-49

PubMed: 25228590 ( click the link to review the publication )

Oncotarget, 2014, 5(15):6512-25

PubMed: 25156567 ( click the link to review the publication )

Oncotarget, 2014, 5(16):7081-92

PubMed: 25216524 ( click the link to review the publication )

Oncotarget, 2014, 5(13):5040-53

PubMed: 24970815 ( click the link to review the publication )

Harvard University, 2014,

PubMed: ( click the link to review the publication )

Oncotarget, 2014, 5(18):8737-49

PubMed: 25228590 ( click the link to review the publication )

Sci Transl Med, 2013, 5(196):196ra98

PubMed: 23903755 ( click the link to review the publication )

Blood, 2013, 121(12):2274-84

PubMed: 23341541 ( click the link to review the publication )
J Clin Invest, 2013, 123(6):2551-63

PubMed: 23635776 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(20):5749-57

PubMed: 23948972 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(9):2584-91

PubMed: 23515407 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(19):5413-22

PubMed: 23888070 ( click the link to review the publication )

Leukemia, 2013, 27(11):2118-28

PubMed: 23535559 ( click the link to review the publication )

Cancer Res, 2013, 73(3):1190-200

PubMed: 23204226 ( click the link to review the publication )

Cell Death Differ, 2013, 21(3):491-502

PubMed: 24362439 ( click the link to review the publication )

Haematologica, 2013, 98(1):57-64

PubMed: 22801959 ( click the link to review the publication )

Oncogene, 2013, 33(9):1190-7

PubMed: 23435426 ( click the link to review the publication )

Sci Signal, 2013, 6(288):ra68

PubMed: 23943608 ( click the link to review the publication )

Sci Signal, 2013, 6(268):ra20

PubMed: 23532334 ( click the link to review the publication )

PLoS Genet, 2013, 9(2):e1003253

PubMed: 23459592 ( click the link to review the publication )

Mol Cancer Ther, 2013, 12(12):2950-61

PubMed: 24107445 ( click the link to review the publication )

J Cell Sci, 2013, 126(Pt 5):1099-108

PubMed: 23345407 ( click the link to review the publication )

Cancer Sci, 2013, 104(8):1027-32

PubMed: 23710822 ( click the link to review the publication )

J Biol Chem, 2013, 288(21):14698-708

PubMed: 23585567 ( click the link to review the publication )

Front Genet, 2013, 4:34

PubMed: 23543623 ( click the link to review the publication )

Cell Cycle, 2013, 12(12):1892-900

PubMed: 23676220 ( click the link to review the publication )

Cancer Med, 2013, 2(1):76-85

PubMed: 24133630 ( click the link to review the publication )

FEBS Lett, 2013, 587(1):5-16

PubMed: 23178716 ( click the link to review the publication )

PLoS One, 2013, 8(10):e77243

PubMed: 24130864 ( click the link to review the publication )

PLoS One, 2013, 8(6):e66306

PubMed: 23824914 ( click the link to review the publication )

Mol Biosyst, 2013, 9(2):234-45

PubMed: 23168618 ( click the link to review the publication )

Biochem Biophys Res Commun, 2013, 435(4):557-61

PubMed: 23665330 ( click the link to review the publication )
Leuk Res, 2013, 38(1):109-15

PubMed: 23981382 ( click the link to review the publication )

J Surg Res, 2013, 184(2):898-906

PubMed: 23602735 ( click the link to review the publication )

Oncotarget, 2013, 4(8):1185-98

PubMed: 23852390 ( click the link to review the publication )

Clin Cancer Res, 2012, 18(9):2502-14

PubMed: 22351686 ( click the link to review the publication )

Clin Cancer Res, 2012, 19(3):657-67

PubMed: 23251002 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2012, 109(31):E2127-33

PubMed: 22773810 ( click the link to review the publication )

Eur J Cancer, 2012, 48(6):936-43

PubMed: 22088482 ( click the link to review the publication )

Cell Death Dis, 2012, 3:e400

PubMed: 23059819 ( click the link to review the publication )

J Cell Sci, 2012, 125(Pt 5):1259-73

PubMed: 22399812 ( click the link to review the publication )

Cancer Sci, 2012, 103(9):1665-71

PubMed: 22703543 ( click the link to review the publication )

Biochim Biophys Acta, 2012, 1823(12):2210-6

PubMed: 22974639 ( click the link to review the publication )

J Leukoc Biol, 2012, 92(1):219-31

PubMed: 22544939 ( click the link to review the publication )

Mol Cell Biol, 2012, 32(22):4674-83

PubMed: 22988297 ( click the link to review the publication )

PLoS One, 2012, 7(8):e44146

PubMed: 22952903 ( click the link to review the publication )

PLoS One, 2012, 7(9):e46518

PubMed: 23029544 ( click the link to review the publication )

Oncotarget, 2012, 3(8):811-23

PubMed: 22885370 ( click the link to review the publication )

Clin Cancer Res, 2011, 17(24):7595-604

PubMed: 22038996 ( click the link to review the publication )

Clin Cancer Res, 2011, 17(8):2260-9

PubMed: 21220474 ( click the link to review the publication )

P Natl Acad Sci USA, 2011, 108(37):E699-708

PubMed: 21876152 ( click the link to review the publication )

Cancer Res, 2011, 71(7):2750-60

PubMed: 21317224 ( click the link to review the publication )

J Invest Dermatol, 2011, 131(2):495-503

PubMed: 21048785 ( click the link to review the publication )

Sci Signal, 2011, 4(192):ra62

PubMed: 21954288 ( click the link to review the publication )

Thyroid, 2010, 20(7):689-95

PubMed: 20578898 ( click the link to review the publication )

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Description

Targets

p110α ^[1] (Cell-free assay)	p110δ ^[1] (Cell-free assay)	p110β ^[1] (Cell-free assay)	p110γ ^[1] (Cell-free assay)	mTOR ^[1] (Cell-free assay)
3 nM	3 nM	33 nM	75 nM	0.58 μM(Ki app)

In vitro

GDC-0941 is equipotent against PI3Kα and PI3Kδ as well as PI3Kα mutants E545-K and H1047-R, displaying modest levels of selectivity against PI3Kβ (10-fold) and PI3Kγ (25-fold), and greater levels of selectivity against members of PI3K class II, III, and IV, including C2β, Vps34, DNA-PK, and mTOR. GDC-0941 potently inhibits the phosphorylation of Akt in U87MG, PC3, and MDA-MB-361 cells with IC50 of 46 nM, 37 nM, and 28 nM, respectively. GDC-0941 inhibits the proliferation of U87MG, A2780, PC3, and MDA-MB-361 cells with IC50 of 0.95 μM, 0.14 μM, 0.28 μM, and 0.72 μM, respectively. ^[1] GDC-0941 treatment potently inhibits the proliferation of both trastuzumab-sensitive and -insensitive HER2-amplified cells with IC50 of 149-944 nM. GDC-0941 inhibits proliferation of HER2-amplified cells that harbor PIK3CA mutations with IC50 of <500 nM, and effectively inhibits both proliferation and viability of HER2-amplified breast cancer cells that are resistant to trastuzumab due to PTEN loss. ^[2] GDC-0941 significantly inhibits the growth of HCT116, DLD1 and HT29 cells with GI50 of 1081 nM, 1070 nM and 157 nM, respectively. ^[3] GDC-0941 inhibits tumor cell proliferation, induces apoptosis and suppresses centroblast population. ^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
Sf9	MmnkT4lv[XOnIFHzd4F6		MlrFNUBp	Ml\rSG1UVw>?	MlnNTY5pcWKrdHnvckBw\iCqdX3hckBz\WOxbXLpcoFvfCCSSUPLJJAyOTCmZXz0ZUBmgHC{ZYPz[YQhcW5iU3[5JINmdGy\|IHPv[ZhxemW\|c3nu[{BxQDWjbIDoZUB4cXSqIFnDOVAhd2ZiMD6wNFMh\|ryP	M372V\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6N{W0OlU1Lz5zOEe1OFY2PDxxYU6=
Sf9	MlfnT4lv[XOnIFHzd4F6		M3HXWFEhcA>?	NInuWmxFVVOR	MYnJcohq[mm2aX;uJI9nKGi3bXHuJJJm[2:vYnnuZY51KFCLM1ugdFEyOGKndHGgTFExPDdvUjDteZRidnRiZYjwdoV{e2WmIHnuJHNnQSClZXzsd{Bkd2W6cILld5NqdmdicEi1ZYxxcGFid3n0bEBKSzVyIH;mJFAvODB\|IN88US=>	NGLmRoE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEe1OFY2PCd-MUi3OVQ3PTR:L3G+
Sf9	M4XQNGtqdmG\|ZTDBd5NigQ>?		MWOxJIg>	MmnCSG1UVw>?	NHTHNZFKdmirYnn0bY9vKG:oIHj1cYFvKHKnY3;tZolv[W62IGDJN2sheDFzMHLleIEhTTV2NT3LJI12fGGwdDDlfJBz\XO\|ZXSgbY4hW2Z7IHPlcIx{KGOxZYjwdoV{e2mwZzDwPFVidHCqYTD3bZRpKEmFNUCgc4YhOC5yMEOg{txO	M1\xRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6N{W0OlU1Lz5zOEe1OFY2PDxxYU6=
Sf9	MYDLbY5ie2ViQYPzZZk>		MmTUNUBp	NFnCXWxFVVOR	MoLkTY5pcWKrdHnvckBw\iCqdX3hckBz\WOxbXLpcoFvfCCSSUPLJJAyOTCkZYThJIV5eHKnc4Pl[EBqdiCVZkmgZ4VtdHNiY3;lfJBz\XO\|aX7nJJA5PWGucHjhJJdqfGhiSVO1NEBw\iByLkCzN{DPxE1?	NEfXXIE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEe1OFY2PCd-MUi3OVQ3PTR:L3G+
Sf9	M3nTU2tqdmG\|ZTDBd5NigQ>?		MY[xJIg>	Mo\MSG1UVw>?	M2nQWmlvcGmkaYTpc44hd2ZiaIXtZY4hemWlb33ibY5idnRiUFmzT{BxOTFyYXzwbIEh\XiycnXzd4VlKGmwIGPmPUBk\WyuczDjc4V5eHKnc4PpcocheDh3YXzwbIE>	MlL1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh5NUS2OVQoRjF6N{W0OlU1RC:jPh?=
MDA-MB-361	NIHVZpFHfW6ldHnvckBCe3OjeR?=		NVTNUI5GOiCq	NEXVZoNFVVOR	NF3OXm1KdmirYnn0bY9vKG:oIFHreEBU\XJ2N{OgdIhwe3Cqb4L5cIF1cW:wIHnuJIh2dWGwIF3ERU1OSi1\|NkGgZ4VtdHNid3n0bEBRUUt\|Q1GgSVU1PS2NIH31eIF1cW:wIIfpeIghUUN3MDDv[kAxNjB{ODFOwG0>	M3zhXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6N{W0OlU1Lz5zOEe1OFY2PDxxYU6=
PC3	NVTLdHBnTnWwY4Tpc44hSXO\|YYm=		MV6yJIg>	M3;OeGROW09?	M2XDU2lvcGmkaYTpc44hd2ZiQXv0JHNmejR5MzDwbI9{eGixconsZZRqd25iaX6gVHRGVi2wdXzsJIh2dWGwIGDDN{Bk\WyuczD3bZRpKEmFNUCgc4YhOC5yM{eg{txO	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDd3NE[1OEc,OTh5NUS2OVQ9N2F-
U87MG	MorPSpVv[3Srb36gRZN{[Xl?		M4TudVIhcA>?	Mn\LSG1UVw>?	M1nlO2lvcGmkaYTpc44hd2ZiQXv0JHNmejR5MzDwbI9{eGixconsZZRqd25iaX6gVHRGVi2wdXzsJIh2dWGwIGW4O21IKGOnbHzzJJdqfGhiSVO1NEBw\iByLkC0OkDPxE1?	NGPnOoI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEe1OFY2PCd-MUi3OVQ3PTR:L3G+
MDA-MB-361	M3PWSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NIXwS\|M6PiCq	M1rKRWROW09?	M3fGVmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVTBMW1DNTN4MTDj[YxteyC5aYToJHBKUzOFQTDFOVQ2NUtibYX0ZZRqd25id3n0bEBKSzVyIH;mJFAvPzJizszN	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDd3NE[1OEc,OTh5NUS2OVQ9N2F-
A2780	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MnfrPVYhcA>?	MVfEUXNQ	NGT0O3ZCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFGyO\|gxKGOnbHzzJJdqfGhiUFnLN2NCKGGwZDDQWGVPKG23dHH0bY9vKHerdHigTWM2OCCxZjCwMlE1KM7:TR?=	M2DqbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6N{W0OlU1Lz5zOEe1OFY2PDxxYU6=
PC3	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M2TkSlk3KGh?	M4HFVGROW09?	NIX6eGNKSzVyPUCuNlgh\|ryP	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDd3NE[1OEc,OTh5NUS2OVQ9N2F-
U87MG	NHnDfJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M3rVeVk3KGh?	M3eweWROW09?	M4G5VmlEPTB;MD65OUDPxE1?	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDd3NE[1OEc,OTh5NUS2OVQ9N2F-
Sf9	NX3DZ4s2U2mwYYPlJGF{e2G7		NXfhb\|FiOzBibXnu	NHHBdXpFVVOR	MYTJcohq[mm2aX;uJI9nKGi3bXHuJHBKO0upYX3tZUBmgHC{ZYPz[YQh[XO\|ZYPz[YQh[XNiYX3veY51KG:oIFHUVEBkd26\|dX3l[EB4cXSqIFnDOVAhd2ZiMD6wOFIh\|ryP	NIH0S5A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkW0PFM1Oid-MkK1OFg{PDJ:L3G+
RAW 264.7	M4H0ZmtqdmG\|ZTDBd5NigQ>?		M1HhR\|kxKG2rbh?=	MWXEUXNQ	NYL6dnhQUW6qaXLpeIlwdiCxZjDoeY1idiCSSUPL[4FudWFiZYjwdoV{e2WmIHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiQVvUJJBpd3OyaH;yfYxifGmxbjD3bZRpKEmFNUCgc4YhOC5{OUig{txO	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjV2OEO0Nkc,OjJ3NEizOFI9N2F-
Sf9	MoTPT4lv[XOnIFHzd4F6		MWGxJIg>		M3XMXGlvcGmkaYTpc44hd2ZiR2PUMYZ2e2WmIHj1cYFvKHKnY3;tZolv[W62IGDJN2tj\XSjIHX4dJJme3OnZDDpckBj[WO3bH;2bZJ2eyCrbn\lZ5Rm\CCVRkmgZ4VtdHNid3n0bEBKSzVyIH;mJFAvODF5IN88US=>	M3;RNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NUSwOlQ2Lz5{M{W0NFY1PTxxYU6=
Sf9	MVzLbY5ie2ViQYPzZZk>		M1vmZ\|EhcA>?		MoqzTY5pcWKrdHnvckBw\iCJU2St[pV{\WRiaIXtZY4hemWlb33ibY5idnRiUFmzT4RmdHSjIHX4dJJme3OnZB?=	NXTZdHhORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1OFA3PDVpPkKzOVQxPjR3PD;hQi=>
Sf9	NWDoc45VU2mwYYPlJGF{e2G7		M2\SR\|EhcA>?		NVLjXnFKUW6qaXLpeIlwdiCxZjDHV3Qu\nW\|ZXSgbJVu[W5icnXjc41jcW6jboSgVGk{U2ejbX3hJIV5eHKnc4Pl[C=>	NIDOXnY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{W0NFY1PSd-MkO1OFA3PDV:L3G+
Sf9	NFfLfWdMcW6jc3WgRZN{[Xl?		NW\PeoN7OSCq		MUHJcohq[mm2aX;uJI9nKEeVVD3meZNm\CCqdX3hckBz\WOxbXLpcoFvfCCSSUPLZYxxcGFiZYjwdoV{e2Wm	MoLWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN3NEC2OFUoRjJ\|NUSwOlQ2RC:jPh?=
SKOV3	MonCT4lv[XOnIFHzd4F6	MVKxJO69VQ>?	NXe4bYRJOSCq	NXzSOmU2TE2VTx?=	MkHZTY5pcWKrdHnvckBw\iCSSUPLZYxxcGFiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCDa4SgV4VzPDd\|IIDoc5NxcG:{eXzheIlwdg>?	NYDvO3NzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzOlA{PDhpPkKzN\|YxOzR6PD;hQi=>
MCF7	NXHE[41TT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NETC[lEyKM7:TR?=	NGiydIo6PiCq	MU\EUXNQ	MVnHTVUxRTBwMEewNkDPxE1?	NIPmcVY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{O2NFM1QCd-MkOzOlA{PDh:L3G+
SKOV3	Mo\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVn4TWJYOSEQvF2=	M{LUfFk3KGh?	MYHEUXNQ	NIrZcnBIUTVyPUCuNVQ4PiEQvF2=	MnHhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN\|NkCzOFgoRjJ\|M{[wN\|Q5RC:jPh?=
PC3	M1PYXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NHvMS2Q4OiCq	NGfwW\|VFVVOR	NIG2R5lKSzVyPUCuNlgh\|ryP	NIDkWlg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUm4NVcyPCd-MkG5PFE4OTR:L3G+
MCF7.1	MmjHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NUPGbHFtPzJiaB?=	NXrESJFbTE2VTx?=	MYDBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2FRkeuNUBk\WyuczDlfJBz\XO\|aX7nJGhGWjJiZ3Xu[UB4cXSqIFnDOVAhd2ZiMD6yPEDPxE1?	NFrKZY89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUm4NVcyPCd-MkG5PFE4OTR:L3G+
MCF7-neo/Her2	M4i4T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NEjXRXo4OiCq	M{HPTWROW09?	NGm5VWJKSzVyPUCuNlkh\|ryP	NGLsXXY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[2NlkxOyd-MkO2OlI6ODN:L3G+
MCF7-neo/Her2	M1PZNWtqdmG\|ZTDBd5NigQ>?				MXfJcohq[mm2aX;uJI9nKFCLM1vhcJBp[SCjc4Pld5Nm\CCjczDy[YR2[3Srb36gc4YhSUuWIIDoc5NxcG:{eXzheIlwdiCjdDDTOFc{KHerdHigTWM2OCCxZjCwMlAxPyEQvF2=	M4\TeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|Nk[yPVA{Lz5{M{[2NlkxOzxxYU6=
PC3	NXT2bpRqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MXi3NkBp	NYfJfpRiTE2VTx?=	NEjuVHRGSzVyPUCuN\|Qh\|ryP	NHu0WGU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUm4OVY{QSd-MkG5PFU3Ozl:L3G+
MCF7.1	M{nqR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MmT2O\|IhcA>?	M3;TemROW09?	MWDBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2FRkeuNUBk\WyuczDlfJBz\XO\|aX7nJHBKO0ujbIDoZUBufXSjboSge4l1cCCHQ{WwJI9nKDBwM{mg{txO	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTl6NU[zPUc,OjF7OEW2N\|k9N2F-
PC3	NFz0XFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M3P2XlczKGh?	M{C0RmROW09?	MkPxRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCSQ{OgZ4VtdHNiZHXmbYNq\W62IHnuJHBVTU5id3n0bEBKSzVyIH;mJFAvOzlizszN	M37SSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMEWwOlY6Lz5{MEC1NFY3QTxxYU6=
MCF7.1	NFS3dpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M4frXlczKGh?	M3\0VGROW09?	NXi4emhkSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNR2Y4NjFiY3XscJMh\XiycnXzd4lv\yCSSUPLZYxxcGFibYX0ZY51KHerdHigTWM2OCCxZjCwMlM1KM7:TR?=	NWrFdYxtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCwOVA3PjlpPkKwNFUxPjZ7PD;hQi=>
MCF7.1	NV7tXmtCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MXG3NkBp		NITuXpBGSzVyPUCuO\|Ih\|ryP	NXrneXdGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCzOFY3PTZpPkKwN\|Q3PjV4PD;hQi=>
NCI-H1975	NUS2d2N6S3m2b4TvfIlkKEG\|c3H5		MYG3NkBp		M{DlRWlEPTB;MD6yO{DPxE1?	NF[5S\|g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{C1PVU1PSd-MkOwOVk2PDV:L3G+
H460	NYC5XFZGS3m2b4TvfIlkKEG\|c3H5		NXrw[HFkPzJiaB?=		NEPOZXJKSzVyPUCuPFch\|ryP	MlrIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNyNUm1OFUoRjJ\|MEW5OVQ2RC:jPh?=
HT-29	MYDDfZRwfG:6aXOgRZN{[Xl?		MkXsO\|IhcA>?		NYjPSJg4UUN3ME2wMlY3KM7:TR?=	NH7WU2o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{C1PVU1PSd-MkOwOVk2PDV:L3G+
HepG2	NWGxRXNXS3m2b4TvfIlkKEG\|c3H5		MlO0O\|IhcA>?		MX7JR\|UxRTFizszN	NI\QWYI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{C1PVU1PSd-MkOwOVk2PDV:L3G+
SGC7901	M4PFdGN6fG:2b4jpZ{BCe3OjeR?=		NYnHbmNmPzJiaB?=		MXLJR\|UxRTFwODFOwG0>	NWfRRplGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOwOVk2PDVpPkKzNFU6PTR3PD;hQi=>
NCI-H226	NF;qVHNEgXSxdH;4bYMhSXO\|YYm=		MnTwO\|IhcA>?		M2TEeGlEPTB;Mj65JO69VQ>?	NGHaNlk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{C1PVU1PSd-MkOwOVk2PDV:L3G+
A549	M{HBXWN6fG:2b4jpZ{BCe3OjeR?=		MXi3NkBp		MnvyTWM2OD14Lkmg{txO	NEC4e4c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{C1PVU1PSd-MkOwOVk2PDV:L3G+
U87MG	NXzOU5VbS3m2b4TvfIlkKEG\|c3H5		NHX5bJY4OiCq		MkDvTWM2OD15Lke3JO69VQ>?	NVnsSlVnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOwOVk2PDVpPkKzNFU6PTR3PD;hQi=>
HBC4	NFjmUmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml\YcI9oT0l3ME2tOk4xOyCP	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjN\|NkK0Okc,OjJ\|M{[yOFY9N2F-
BSY1	NVPWU3oxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYLsc4dIUTVyPT22MlkxKE1?	NVnrR\|NnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKzN\|YzPDZpPkKyN\|M3OjR4PD;hQi=>
HBC5	M1HBdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4\wdYxw\0eLNUC9MVYvPjBiTR?=	MlHXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ\|M{[yOFYoRjJ{M{O2NlQ3RC:jPh?=
MCF7	NX7XR5dmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2P4VYxw\0eLNUC9MVcvOzNiTR?=	M1Tl[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{M{O2NlQ3Lz5{MkOzOlI1PjxxYU6=
MDA-MB-231	NHjxdVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYPsc4dIUTVyPT21MlQ3KE1?	M1jNXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{M{O2NlQ3Lz5{MkOzOlI1PjxxYU6=
U251	M4nkRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3LrdIxw\0eLNUC9MVUvPTBiTR?=	MlX5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ\|M{[yOFYoRjJ{M{O2NlQ3RC:jPh?=
SF268	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlLKcI9oT0l3ME2tOU4{QSCP	MnHPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ\|M{[yOFYoRjJ{M{O2NlQ3RC:jPh?=
SF295	M3u4OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MofocI9oT0l3ME2tOk4{PyCP	Mlr5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ\|M{[yOFYoRjJ{M{O2NlQ3RC:jPh?=
SF539	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1u5fIxw\0eLNUC9MVYvPTBiTR?=	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjN\|NkK0Okc,OjJ\|M{[yOFY9N2F-
SNB75	M2rxPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mln1cI9oT0l3ME2tO{4yOCCP	MnOzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ\|M{[yOFYoRjJ{M{O2NlQ3RC:jPh?=
SNB78	NHHzNnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NI\oZWltd2eJSUWwQU03NjV{IF2=	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjN\|NkK0Okc,OjJ\|M{[yOFY9N2F-
HCC2998	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3;aRYxw\0eLNUC9MVYvOjliTR?=	M3WxUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{M{O2NlQ3Lz5{MkOzOlI1PjxxYU6=
KM12	NHn1dGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnfxcI9oT0l3ME2tOU44PiCP	NFzTZYE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkOzOlI1Pid-MkKzN\|YzPDZ:L3G+
HT-29	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2PSZoxw\0eLNUC9MVYvOzBiTR?=	M{\kbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{M{O2NlQ3Lz5{MkOzOlI1PjxxYU6=
HCT15	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYX2VmxndG:pR1m1NF0uPi5zMjDN	NUn1VHEzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKzN\|YzPDZpPkKyN\|M3OjR4PD;hQi=>
HCT116	M{f6T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIHjRZRtd2eJSUWwQU02Njh5IF2=	MmfEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ\|M{[yOFYoRjJ{M{O2NlQ3RC:jPh?=
NCI-H23	M3LXcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYPsc4dIUTVyPT21Mlc{KE1?	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjN\|NkK0Okc,OjJ\|M{[yOFY9N2F-
NCI-H226	NYP5UpBrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1Hyb4xw\0eLNUC9MVYvOjFiTR?=	NFzCTIg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkOzOlI1Pid-MkKzN\|YzPDZ:L3G+
NCI-H522	NGruSmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVXsc4dIUTVyPT22MlU5KE1?	M3\XZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{M{O2NlQ3Lz5{MkOzOlI1PjxxYU6=
NCI-H483	NWrKSI9zT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmmzcI9oT0l3ME2tOk42PiCP	NV\kc\|V6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKzN\|YzPDZpPkKyN\|M3OjR4PD;hQi=>
A549	NIG4NodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFnDNpVtd2eJSUWwQU03NjF3IF2=	MnLhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ\|M{[yOFYoRjJ{M{O2NlQ3RC:jPh?=
DMS273	M{nVeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4TkbYxw\0eLNUC9MVYvPDNiTR?=	Mn;PQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ\|M{[yOFYoRjJ{M{O2NlQ3RC:jPh?=
DMS114	MofpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX7sc4dIUTVyPT21MlkzKE1?	NEH0b3U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkOzOlI1Pid-MkKzN\|YzPDZ:L3G+
LOXIMVI	M4PaXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFPHNHZtd2eJSUWwQU03NjJ7IF2=	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjN\|NkK0Okc,OjJ\|M{[yOFY9N2F-
OVCAR3	M2XOU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX76S3BrdG:pR1m1NF0uPi55MTDN	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjN\|NkK0Okc,OjJ\|M{[yOFY9N2F-
OVCAR4	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXXZ[3IxdG:pR1m1NF0uPS55NjDN	NWPSTFBSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKzN\|YzPDZpPkKyN\|M3OjR4PD;hQi=>
OVCAR5	M{flNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{fTRoxw\0eLNUC9MVYvOjZiTR?=	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjN\|NkK0Okc,OjJ\|M{[yOFY9N2F-
OVCAR8	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGK3cnNtd2eJSUWwQU02Njd\|IF2=	NWe3PFkzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKzN\|YzPDZpPkKyN\|M3OjR4PD;hQi=>
SKOV3	NXPoRZJlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2fzeYxw\0eLNUC9MVYvPTJiTR?=	NX;Rbmw3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKzN\|YzPDZpPkKyN\|M3OjR4PD;hQi=>
RXF631L	MlXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWjsc4dIUTVyPT22Mlg5KE1?	NG\NWVM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkOzOlI1Pid-MkKzN\|YzPDZ:L3G+
ACHN	Mlz2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXHZU5MydG:pR1m1NF0uPi5yNzDN	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjN\|NkK0Okc,OjJ\|M{[yOFY9N2F-
St-4	MmXGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4XWVoxw\0eLNUC9MVUvPTZiTR?=	NGT4bYk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkOzOlI1Pid-MkKzN\|YzPDZ:L3G+
MKN1	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH;0SI9td2eJSUWwQU04NjB6IF2=	NXG4V\|RKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKzN\|YzPDZpPkKyN\|M3OjR4PD;hQi=>
MKN7	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlvXcI9oT0l3ME2tOk42OCCP	M1zWd\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{M{O2NlQ3Lz5{MkOzOlI1PjxxYU6=
MKN28	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXXwZo5xdG:pR1m1NF0uPS53MjDN	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjN\|NkK0Okc,OjJ\|M{[yOFY9N2F-
MKN45	NHGwdJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV3JR5JidG:pR1m1NF0uPi53NTDN	M{mzTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{M{O2NlQ3Lz5{MkOzOlI1PjxxYU6=
MKN74	NHS1dmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{fXdIxw\0eLNUC9MVYvODJiTR?=	M4HEN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{M{O2NlQ3Lz5{MkOzOlI1PjxxYU6=
DU145	MlTNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2jIZYxw\0eLNUC9MVUvQDViTR?=	NHXhS4Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkOzOlI1Pid-MkKzN\|YzPDZ:L3G+
PC3	NVfiOVJKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2WyXYxw\0eLNUC9MVYvPjZiTR?=	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjN\|NkK0Okc,OjJ\|M{[yOFY9N2F-
ES5	NH[1foNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYr4PW5HUUN3ME21NE4zOSCwTR?=	MknSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
HH	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV\NVFJuUUN3ME2xNVEvODhibl2=	NHyxOWs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
MHH-PREB-1	MoD5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3PyN2lEPTB;MUG0MlMhdk1?	MlHxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
NCI-H1770	Ml3qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mmr0TWM2OD1zMkOuPFYhdk1?	MkC1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
HuO9	M3qzc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH\KTlBKSzVyPUKwOk4xOiCwTR?=	M17VXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
HAL-01	NIHzZ29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{\pPWlEPTB;MkC2Mlc{KG6P	M2DpelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
NOS-1	NHjBRYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIX3d3FKSzVyPUKxNU45OiCwTR?=	M2L4cFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
HGC-27	MojES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXrJR\|UxRTJzMj61O{BvVQ>?	NHPFSoM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
NB69	NIjze4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVz2W2w3UUN3ME2yOFUvOjdibl2=	NWnIc2Z7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
RS4-11	M2HGPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4PVeGlEPTB;Mk[xMlc3KG6P	M{Hkb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
DOK	NGq3WGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIXXNFJKSzVyPUOwNU44KG6P	M3f4TlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
LB2241-RCC	NXXWWnRZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHTzNoNKSzVyPUOwN{45PCCwTR?=	M3\mdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
NCI-H1623	NVvGbHMyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnnFTWM2OD1\|MESuNFghdk1?	NIHXc5A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
YH-13	MkfrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NU\aN41oUUN3ME2zNFQvOzJibl2=	NYjDbI5KRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
BPH-1	NGftW41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVrJR\|UxRTNzNDDuUS=>	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
AN3-CA	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUPk[ZI{UUN3ME2zOFAvOzdibl2=	M4LkZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
ES7	M1jMNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmnFTWM2OD1\|NEGuPVkhdk1?	NHrBSGY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
MDA-MB-175-VII	MnrHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEfQOoxKSzVyPUO1Nk46OiCwTR?=	MmrMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
GAMG	M{PvZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mlr2TWM2OD1\|N{CuPFUhdk1?	MoX3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
CHL-1	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnvvTWM2OD1\|N{iuOlUhdk1?	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
NB7	NYDkcWRCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYXJR\|UxRTN6OT64N{BvVQ>?	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
MFE-280	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWDJR\|UxRTRzOD6yJI5O	M1v2R\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
HL-60	M4nyW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH\SdWdKSzVyPUSyOU44PSCwTR?=	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
GCIY	NE\IdldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlXvTWM2OD12M{OuPEBvVQ>?	NX7SO4JORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
MDA-MB-361	M2DjSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVrJR\|UxRTR\|OT6xN{BvVQ>?	NYCzOlA6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
LXF-289	NYf1ZmJzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1X0VGlEPTB;NES4MlI4KG6P	M4XJflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
NBsusSR	MknaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1\rfWlEPTB;NEi4Mlg2KG6P	M4DEPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
KU-19-19	MnXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmLsTWM2OD13MU[uNFchdk1?	M4XBOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
A204	NVLSeIZ4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHvWNnlKSzVyPUWyNk4{OyCwTR?=	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
LB1047-RCC	NH30bXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVjJR\|UxRTV{Mj65N{BvVQ>?	M1\QVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
COLO-684	NFPSNWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVHJR\|UxRTV{Mz6xNUBvVQ>?	NVzBdWdqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
PA-1	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn7MTWM2OD13M{KuOFEhdk1?	NWjBb3kxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
MG-63	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2HZPWlEPTB;NUSxMlEyKG6P	NFP6PIk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
BHT-101	MoWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnXTTWM2OD13NESuPVQhdk1?	MoXXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
NKM-1	MlXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MULJR\|UxRTV7Mz6wPUBvVQ>?	NEXMV4Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
T47D	M{P1XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYTJR\|UxRTV7Nz61OkBvVQ>?	M3TNdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
MOLT-4	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn3MTWM2OD14MkOuOlIhdk1?	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
IGROV-1	Mm\rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUH0cZdEUUN3ME22N\|QvOzFibl2=	NUG1eGdQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
ES4	MmjSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFz4b4ZKSzVyPU[zPU42PCCwTR?=	M{m4XFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
HuO-3N1	NEDkT3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3LPWmlEPTB;NkSyMlM5KG6P	M4nmcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
NEC8	NFfLRmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWG2ZYRyUUN3ME22OVMvPTdibl2=	NEmzSnY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
HO-1-N-1	NILqepdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnPYTWM2OD14NUmuNVchdk1?	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
EPCL-272H	NEXNU4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUPJR\|UxRTZ6Nz6yNUBvVQ>?	NVTzXG1kRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
D-263MG	NIjxVJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHfwd2FKSzVyPUexPE4yKG6P	NY\HNYZ5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
MV-4-11	MkS4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmfxTWM2OD15MkSuN\|Ehdk1?	M3y3U\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
SK-NEP-1	MknzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1jKS2lEPTB;N{K1Mlk1KG6P	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
SW872	M33vcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M33Q[WlEPTB;N{K3Mlg6KG6P	NEPJXYw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
P30-OHK	MoLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUXJR\|UxRTd\|MD63NUBvVQ>?	NIfBV4U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
OMC-1	Ml7aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml3hTWM2OD15NUGuNFkhdk1?	MoO2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
LoVo	NGL0dnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkTYTWM2OD15N{euPUBvVQ>?	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
LNCaP-Clone-FGC	MlS3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3vZS2lEPTB;N{m2MlM1KG6P	M2HGeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
L-363	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHSwVJhKSzVyPUe5PE41OiCwTR?=	MkWyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
ES8	NI\mSXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYPqTlRqUUN3ME24NVAvPTJibl2=	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
697	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2KyXmlEPTB;OEOxMlU2KG6P	MnPEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
HSC-3	NGC3OXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NI\mPGhKSzVyPUizPU42PCCwTR?=	NGnke5Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
H4	NFK4V5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXvwVJhJUUN3ME24OVAvQDVibl2=	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
QIMR-WIL	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX7JR\|UxRTh4NT6yJI5O	NW[3W\|NqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
OAW-42	M37nOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoD1TWM2OD16N{KuNVkhdk1?	M2nw[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
MCF7	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXPLfpJ3UUN3ME24PVgvPTlibl2=	M2PDNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
SCC-25	NEDoN4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX:wXoc2UUN3ME25NVQvOTlibl2=	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
NCI-H1563	NV7VWHFET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHe2NZNKSzVyPUmxOU46QSCwTR?=	MmPsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
OVCAR-5	M4\se2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXXa[lBPUUN3ME25OFAvOTdibl2=	NXf6dI9bRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
HDLM-2	NITCcopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFn1cHdKSzVyPUm0PU4zKG6P	M2TKPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
NB5	MmSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3nEcGlEPTB;OUW2MlYhdk1?	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
NCI-H292	MmfMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFzReWNKSzVyPUm3OE4{OiCwTR?=	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
A101D	NYfJXmlXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWTJR\|UxRTl7MD6xPUBvVQ>?	Mk\3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
NCI-H1648	NH7lVHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2rSR2lEPTB;OUm4MlUyKG6P	Mm\1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
EKVX	NWH6cGp6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnPxTWM2OD1zLkCxNlkh\|ryP	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
SW1710	M3;FNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGHmc4xKSzVyPUGuNFQzOzNizszN	M37HcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
WM-115	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4PBSmlEPTB;MT6wOlY2PiEQvF2=	NXv5b\|l2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
CAL-54	NHezZ3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoLnTWM2OD1zLkC3NFgyKM7:TR?=	NXHQRpVkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
TGBC24TKB	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{DRWWlEPTB;MT6wPFA1PSEQvF2=	NVj1NGZlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
NCI-H520	MnfKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnLuTWM2OD1zLkC4PVY4KM7:TR?=	NW\CWZBlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
D-423MG	NWjhZo1CT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{\PPGlEPTB;MT6wPVk3OiEQvF2=	M{DQcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
BFTC-905	M1z4WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXPZPY45UUN3ME2xMlE{PDR7IN88US=>	M1vX[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
HT	NGfzfpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2\VeGlEPTB;MT6xN\|Q4QCEQvF2=	NHr2SWg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
CTB-1	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV\rdINJUUN3ME2xMlE1Ojl\|IN88US=>	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
Hs-578-T	NHnOcppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFPTeVZKSzVyPUGuNVk2PjVizszN	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
HuH-7	M1XsXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHe5V\|RKSzVyPUGuNlA6PDlizszN	MkK1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
LB996-RCC	M1rCS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mmm4TWM2OD1zLkKyNVc4KM7:TR?=	M{XLVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
KYSE-270	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVTJR\|UxRTFwMkm3N\|Qh\|ryP	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
A4-Fuk	M1iwS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVnJR\|UxRTFwMkm5PVMh\|ryP	NUXaTVBTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
A498	NEXheVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2XFeWlEPTB;MT6zNFQ4PCEQvF2=	NF7rU209[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
SK-MEL-1	NETSeGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1zzOGlEPTB;MT6zNFY4QSEQvF2=	NVjXXHhZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
AU565	MnfOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{mwWmlEPTB;MT6zNVg3OyEQvF2=	NEXneoQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
Saos-2	Mm\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGryWopKSzVyPUGuN\|MzODVizszN	Mk\qQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
A549	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWm0bFhtUUN3ME2xMlM6QTdizszN	M3jXTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
BFTC-909	MoTMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWD2cHdsUUN3ME2xMlQ{OzB3IN88US=>	MofIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
MDA-MB-415	M4W0PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWXJR\|UxRTFwNEi2PVIh\|ryP	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
639-V	NIXMO3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3T6OmlEPTB;MT61NFI1PSEQvF2=	MmTPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
A704	NFfxfHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWHJR\|UxRTFwNUC3PFUh\|ryP	NGe5[VI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
PANC-03-27	NUfJbo9OT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVTJR\|UxRTFwNUG0NFgh\|ryP	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
SK-MEL-28	NUjOPXRyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mmm5TWM2OD1zLkW2NFg2KM7:TR?=	M4TOb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
Ramos-2G6-4C10	MnPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUDJR\|UxRTFwNkC3OFYh\|ryP	MmXFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
HuP-T4	NVT6dWdoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYXQe5VGUUN3ME2xMlYxPzd6IN88US=>	Mn7rQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
VA-ES-BJ	NGGwbo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYjJR\|UxRTFwNkGyO{DPxE1?	NFLPNHA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
EFM-19	NYjBVG1JT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlryTWM2OD1zLk[xPFEh\|ryP	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
G-401	M3LTWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmPKTWM2OD1zLk[yNVY1KM7:TR?=	NF\5dpo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
D-566MG	NUDHfnZPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3n3V2lEPTB;MT62NlU{KM7:TR?=	NV7UOo93RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
JVM-3	M2W1OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MY\JR\|UxRTFwNkS4O\|Uh\|ryP	M4jzR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
TK10	M120PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4XOemlEPTB;MT62O\|A5OyEQvF2=	NGHuVZA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
BT-20	NIK0VZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnLaTWM2OD1zLk[4PVAzKM7:TR?=	NXzHOG42RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
EGI-1	NVG2dnlqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYfJR\|UxRTFwOES3NFEh\|ryP	MkfEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
EW-16	NILLPGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlLGTWM2OD1zLki1NVgzKM7:TR?=	NWXKNJptRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
NCI-H2228	NECwO49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV\JR\|UxRTFwOEWyNFMh\|ryP	Mkj1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
BB49-HNC	M1vl[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXzJR\|UxRTFwOEi2PVIh\|ryP	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
G-402	NXTmSYN5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX3oZWpQUUN3ME2xMlg6Pzl5IN88US=>	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
NCI-H526	NWO3VHNtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHnmb3JKSzVyPUGuPVE{QSEQvF2=	NX;rRnpGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
ME-180	M4LVRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX7JR\|UxRTFwOUO0O\|ch\|ryP	MmiyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
PFSK-1	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHzXV3JKSzVyPUGuPVQ1PThizszN	NX;UdpdZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
TYK-nu	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFXnNGdKSzVyPUGuPVU5OjNizszN	NXHL[Vh4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
HOS	NIrUU4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUPH[XNzUUN3ME2xMlk4QTR6IN88US=>	NULpdm96RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
T98G	M{TBRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXr1XnFOUUN3ME2xMlk6ODB4IN88US=>	Mo[1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
SK-MES-1	NHfGV\|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUPD[XV{UUN3ME2yMlAyOzN{IN88US=>	NF[zd489[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
SNB75	MmDwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEnYUW1KSzVyPUKuNFE2PDFizszN	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
LAMA-84	NGjrSXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWjGbnFsUUN3ME2yMlAzPjh7IN88US=>	MlzoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
CAL-39	MnTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkDWTWM2OD1{LkCzNlgh\|ryP	MnHLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
LOXIMVI	NWjKcIpRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{DtOGlEPTB;Mj6wOFA5PCEQvF2=	M4PNUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
NH-12	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUHJR\|UxRTJwMEW0NlQh\|ryP	NULZOpNZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
NCI-H1048	NXOwOoJ{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWLJR\|UxRTJwMUC1NkDPxE1?	M4TEeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
KS-1	NUD0fVZ6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1v5XWlEPTB;Mj6xNVAxOSEQvF2=	NWHLd2xzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
NCI-N87	MomxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYH3WG1tUUN3ME2yMlE{Ozh2IN88US=>	NUDBcmFyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
CHP-212	Mm\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUDJR\|UxRTJwMUi0OFIh\|ryP	NUPOcnJQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
HCC1419	MnzES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkfPTWM2OD1{LkKxNVE2KM7:TR?=	M1HpNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
ES1	NEH5PY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYL2OZJXUUN3ME2yMlIyOzJ4IN88US=>	M2jNN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
NCI-H2030	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M33oWmlEPTB;Mj6yOFEzOyEQvF2=	M3rsWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
EW-22	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MW\JR\|UxRTJwMkWwOlch\|ryP	M1juWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
A431	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIi4[ZJKSzVyPUKuNlc{PTRizszN	NYT0O4hTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
SF126	MojKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4[4OWlEPTB;Mj6zNFYzPSEQvF2=	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
SF295	NXHmTGZIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkfnTWM2OD1{LkOxOVI1KM7:TR?=	M2nz[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
D-502MG	NV\sd2pUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUXmS3U2UUN3ME2yMlMzPDZzIN88US=>	M2PmbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
HCC2157	NWjqcGpFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYLJR\|UxRTJwM{K5Nlch\|ryP	NITRN2I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
D-283MED	NV71SI8xT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYLJR\|UxRTJwM{W5NlYh\|ryP	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
SNU-423	NVnrfo1zT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYnJR\|UxRTJwNECxO\|Eh\|ryP	NF3hUmY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
SK-LU-1	MoTGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYrJR\|UxRTJwNES1PFYh\|ryP	NYH3[45rRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
22RV1	NH:wOlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{XubWlEPTB;Mj60OVYyPyEQvF2=	M3n1T\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
SW1088	NXjyeIpWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX\sdVJmUUN3ME2yMlQ6OjF\|IN88US=>	NFrleIk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
HT-3	MoLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXXJR\|UxRTJwNEmyOVkh\|ryP	M2L5blxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
NCI-H1666	NFPacY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1\pdmlEPTB;Mj61NVExPCEQvF2=	MoDvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
EM-2	M3fDZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEC1fYNKSzVyPUKuOVEyPjlizszN	NFjwOIM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
SNU-449	MkTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2Kz[GlEPTB;Mj61O\|AyPCEQvF2=	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
786-0	M{jnSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVPJR\|UxRTJwNUmyN\|gh\|ryP	NWH0PHR4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
SKG-IIIa	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX3JR\|UxRTJwNkW5N\|kh\|ryP	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
MEL-HO	NUjZdXRkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGrWWYFKSzVyPUKuOlc3OzRizszN	M1q0VVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
LCLC-97TM1	M1nFVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX3JR\|UxRTJwNkmyOlch\|ryP	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
MKN7	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYDRfWFiUUN3ME2yMlcxPzV2IN88US=>	NILpXYE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
5637	MlrkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2LTXmlEPTB;Mj63NVA{PSEQvF2=	NXP0ZnpNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
HOP-92	M{fKeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX7JR\|UxRTJwN{S3NVch\|ryP	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
MDA-MB-157	MmXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Moi1TWM2OD1{LkiyNFI{KM7:TR?=	NUS5UnFRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
NB12	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIXNelNKSzVyPUKuPFQ6OTRizszN	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
DMS-273	NX7VZYN6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFLSUIdKSzVyPUKuPFY1PyEQvF2=	M3;wPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
HCC70	MoXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3vVZWlEPTB;Mj64OlU5QSEQvF2=	M{\RSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
YKG-1	MmCyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFjiNJBKSzVyPUOuNFM4QDdizszN	NWXtWW85RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
NCI-H28	MmHmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVTZVm1qUUN3ME2zMlA2OjlzIN88US=>	M4O0NVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
HN	M1S3bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MorDTWM2OD1\|LkC2OlM3KM7:TR?=	M{LtRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
HT-1080	M{jTVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHjVTphKSzVyPUOuNFg3ODZizszN	NVniO3Z[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
HPAF-II	NH;3VVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnjQTWM2OD1\|LkGwNFY5KM7:TR?=	NETnZpc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
U-2-OS	NGXTPJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4\veGlEPTB;Mz6xN\|c5OiEQvF2=	MnXuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
SNU-387	NFvmPJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2rhXWlEPTB;Mz6xOlM3PCEQvF2=	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
Becker	M3y4SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEXJU5lKSzVyPUOuNVY5ODhizszN	M3HQV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
BHY	NV;oe4J3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWXJR\|UxRTNwMkW1O\|Eh\|ryP	NGjOboU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
HTC-C3	M3PuVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3jKZWlEPTB;Mz6yPVM2OiEQvF2=	NGHNfVg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
M14	NHv2c2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEPaXmtKSzVyPUOuN\|A3PjNizszN	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
COR-L23	NIfSboJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2\hRmlEPTB;Mz6zO\|I4QSEQvF2=	MkWwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
C32	NIDlTpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWnXe4M{UUN3ME2zMlQyPTB6IN88US=>	NXzGb5NtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
Mewo	NHvabIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYHkSG46UUN3ME2zMlQzOTh{IN88US=>	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
TE-8	NWj4VWhET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX\sVXFZUUN3ME2zMlQ5OjV7IN88US=>	MkH0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
RPMI-2650	NYLGc5dKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX3JR\|UxRTNwNkC2N\|ch\|ryP	NHvseGE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
AGS	Mlv4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnTNTWM2OD1\|Lk[yOFY1KM7:TR?=	NWnWO29TRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
MZ2-MEL	Ml7FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlvETWM2OD1\|Lk[2NVM5KM7:TR?=	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
Calu-3	MlG5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NE\GOWFKSzVyPUOuO\|EzQDdizszN	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
SJSA-1	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3iwfWlEPTB;Mz63NVMyPSEQvF2=	Mkm5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
SW962	M1HTPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn;KTWM2OD1\|LkeyOlM3KM7:TR?=	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
PC-14	NGHGbVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIT4XGJKSzVyPUOuO\|MzOjJizszN	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
SW1573	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHTM[HNKSzVyPUOuO\|U{PDhizszN	M{XVNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
769-P	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3W2U2lEPTB;Mz64Nlc1OyEQvF2=	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
KNS-62	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlLnTWM2OD1\|LkmyN\|M5KM7:TR?=	NXnFeY9KRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
NCI-H747	Mk\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFrpVVhKSzVyPUSuNFU3OzhizszN	NIHWZWQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
LN-405	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mof4TWM2OD12LkG1O\|I5KM7:TR?=	NXvldYJwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
OVCAR-8	M3LYeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NULHR3VmUUN3ME20MlIzPTR\|IN88US=>	NFLqb4o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
DMS-114	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWfJR\|UxRTRwMkO4PVEh\|ryP	M{\FOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
NCI-H2126	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGXXTmlKSzVyPUSuNlQ2PThizszN	M2XKSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
TCCSUP	MoLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2fuUWlEPTB;ND6yOFc5QCEQvF2=	NET1R4M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
SK-N-FI	NXyyWlJiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2HZVmlEPTB;ND6yOVM{OiEQvF2=	MmfUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
HCE-4	NVXSdYI{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUXWUo5UUUN3ME20MlI4OTl5IN88US=>	NEnjW3E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
DK-MG	NEjEVJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFXGeVdKSzVyPUSuN\|A{QSEQvF2=	M1X4d\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
RO82-W-1	NWj6cWJPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX61dJN2UUN3ME20MlMzPTh2IN88US=>	MoPqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
A2780	MmLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NETUOnVKSzVyPUSuN\|Y3QDJizszN	NUHhR5N4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
ETK-1	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV;qSXB1UUN3ME20MlM4ODV{IN88US=>	Ml;4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
FADU	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFvYO4RKSzVyPUSuN\|c1PjdizszN	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
CAL-12T	MnXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmexTWM2OD12LkSxOFE{KM7:TR?=	NWjhZmI{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
647-V	NGS1T21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmP5TWM2OD12LkS0NFIzKM7:TR?=	Moj3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
TGBC1TKB	M{HNUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGixdmNKSzVyPUSuOFUyOTNizszN	NIrreng9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
LU-99A	NXPZdXp6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYXJR\|UxRTRwNE[wOkDPxE1?	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
CAL-33	NUPmUpFRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnzXTWM2OD12LkWyOFU3KM7:TR?=	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
LU-134-A	NEfyZ4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVfJR\|UxRTRwNUK3OFUh\|ryP	M1zzVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
NCI-H1355	NWLYOFFJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF7l[mpKSzVyPUSuOVUyPDZizszN	MkT2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
RPMI-7951	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWjVdmY4UUN3ME20MlU4ODB{IN88US=>	NYTEOmhjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
TE-1	NYq4b3JYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGfDO3NKSzVyPUSuOlYyPDNizszN	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
OE33	Mn;pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1HXVWlEPTB;ND63NFUyOSEQvF2=	NHLtVnA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
CAL-51	M{fFTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH;CTm5KSzVyPUSuO\|ExQDJizszN	NVfFfldVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
SW1783	MnzqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3n3N2lEPTB;ND63OVMxQCEQvF2=	NGPtfpU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
BT-474	NELOWpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn\2TWM2OD12Lke2N\|g1KM7:TR?=	NV:3TopGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
KYSE-520	Mln1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUDmNHM1UUN3ME20Mlg4Ozl{IN88US=>	NU\MRlJlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
8-MG-BA	NEDVO3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmP4TWM2OD12Lki4OVU4KM7:TR?=	NIrWNZU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
IA-LM	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{nlPWlEPTB;ND65PVQ{PSEQvF2=	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
SW954	MlLYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVnJR\|UxRTRwOUm0OFMh\|ryP	NHzNTYQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
RPMI-8226	NHjwe4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoPlTWM2OD13LkC1OFYyKM7:TR?=	NX\RbXJQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
MKN1	NFnZbYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4HaSmlEPTB;NT6wO\|kzPyEQvF2=	NVrEfZZtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
A375	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXfJR\|UxRTVwMEmyOVYh\|ryP	MorkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
8305C	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH;mcmhKSzVyPUWuNFk5QDdizszN	M4jreVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
CAL-62	M4q2fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnLOTWM2OD13LkG4NlU6KM7:TR?=	NUH1eVFtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
NB10	NF\iSnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NInNcotKSzVyPUWuNlI4PDRizszN	M{fmRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
OC-314	M37LeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3zMfGlEPTB;NT6zO\|Q1PCEQvF2=	NGOwVJA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
PSN1	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHz1fIpKSzVyPUWuN\|gzQDZizszN	NGq5XIk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
GR-ST	M1z4d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYXJR\|UxRTVwM{izNlIh\|ryP	NVK0XGdjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
P12-ICHIKAWA	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MljPTWM2OD13LkSwNUDPxE1?	Mo\SQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
NCI-H1092	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHfFbYFKSzVyPUWuOFEyPDhizszN	NWnFW\|BIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
SCC-4	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnHQTWM2OD13LkSxN\|U2KM7:TR?=	NFjSR2c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
TE-6	NVTKWopiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2HEdmlEPTB;NT60NVgyPiEQvF2=	NHHzZlM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
DOHH-2	M4Lhemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYXHU4N4UUN3ME21MlQzOjR6IN88US=>	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
SW684	NHnEWFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlHpTWM2OD13Lk[2N\|g2KM7:TR?=	NIXm[Fg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
CP50-MEL-B	MnrxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmX2TWM2OD13Lk[4Olg1KM7:TR?=	MnH1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
UM-UC-3	M1fX[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWfpeGNOUUN3ME21MlczOjNzIN88US=>	NVXrbnd7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
LC-2-ad	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWr0fmNmUUN3ME21Mlc5OjVzIN88US=>	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
PC-3	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWDJR\|UxRTVwOUG2NVUh\|ryP	NUH4dmR1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
CAN	M3WxNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIThWVhKSzVyPUWuPVI5OiEQvF2=	NVLLO\|BbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
ESS-1	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NY\We3U1UUN3ME21Mlk4QDZ7IN88US=>	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
ATN-1	M2DXcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWrG[5dIUUN3ME22MlA2PTZ6IN88US=>	NVrMdot6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
BxPC-3	Mmn3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYTJR\|UxRTZwMEiyNVkh\|ryP	NF;XbmY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
KYSE-150	M1nnUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mmi4TWM2OD14LkGyOFc3KM7:TR?=	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
RPMI-8866	NYnadIp[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoXjTWM2OD14LkG5NVY{KM7:TR?=	NXHRcJltRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
SW780	NGnJVlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFi3VWlKSzVyPU[uNlA1OiEQvF2=	MomwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
A388	NYXvOI94T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHvRTZpKSzVyPU[uNlMyOTVizszN	NVTqfms3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
NCI-H1437	NH3CdlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXvhUINwUUN3ME22MlI1ODd\|IN88US=>	NWS3PG9ERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
NCI-H1755	NVrhc2NsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mkj6TWM2OD14LkO2OlEzKM7:TR?=	M{jCXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
LS-123	NVzFW49PT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWT4XHYyUUN3ME22MlQxPTJzIN88US=>	Mkj6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
CaR-1	NUnXb2JFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVTJR\|UxRTZwNE[zO\|Mh\|ryP	NYPUfppHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
RT-112	MlrkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3L6NGlEPTB;Nj62NFM{QCEQvF2=	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
CGT	M1zhS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3zDXmlEPTB;Nj63N\|Y5OSEQvF2=	NFTDdoc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
SW626	M2DaR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlzNTWM2OD14LkezPVQ3KM7:TR?=	Ml;PQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
AsPC-1	NXT4[G5wT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NETGcJdKSzVyPU[uO\|Q2ODdizszN	NF3sO2k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
SBC-5	NEnRNphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2\TdGlEPTB;Nj65O\|I6PyEQvF2=	NUTEVVU1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
SF539	NIrqTIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2HDfmlEPTB;Nj65PVM{OyEQvF2=	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
TI-73	NFfBdWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mmn0TWM2OD15LkC2Nlg2KM7:TR?=	NFixfVI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
MHH-ES-1	MoT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{C5XmlEPTB;Nz6wO\|c3OiEQvF2=	NV7JTWp5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
KYSE-510	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHOzXGdKSzVyPUeuNFg1OzJizszN	NF3S[Gs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
EW-1	NUD4WmFNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGHTV2FKSzVyPUeuN\|Y6QTZizszN	NF6xd5k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
SK-OV-3	NGe2U4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnjZTWM2OD15LkO5OFMzKM7:TR?=	M3jPSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
MC-IXC	M{TpXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYjCNYpJUUN3ME23MlQyQTd{IN88US=>	NHLzUJY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
HSC-2	NIKzOGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlvFTWM2OD15LkSyO\|A2KM7:TR?=	MkjnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
NCI-H2342	Ml36S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXH4WlFuUUN3ME23MlUyPDlizszN	MlfZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
NCI-H1792	NF7aU4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUDzOVZNUUN3ME23MlUyPzFzIN88US=>	M{LpSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
HT-1376	M1;GUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXnJR\|UxRTdwOEe3O\|gh\|ryP	NYO0NXRmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
EW-13	M3TaN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkTtTWM2OD15Lki5PVc4KM7:TR?=	MoPNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
no-11	NWXwNoNxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIHCSoRKSzVyPUeuPVAyPzRizszN	MlPEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
Daoy	M4fVOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVPiZmdNUUN3ME23Mlk1OzJzIN88US=>	Mnn2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
COLO-800	NVzNWGQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1nVeGlEPTB;OD6wOFE3OiEQvF2=	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
GB-1	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3nSUWlEPTB;OD6wOlU3PSEQvF2=	Ml7aQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
SJRH30	M2DZXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2PtT2lEPTB;OD6xOVg4QCEQvF2=	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
NCI-H2291	M1mycWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFXLR\|NKSzVyPUiuNlkyQDdizszN	NX3a[GZnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
J82	Mnj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{f4WWlEPTB;OD6yPVQ6OSEQvF2=	M1HrT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
NCI-H596	M3XZTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NG\h[3pKSzVyPUiuN\|E1PTNizszN	NEDpZnY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
RERF-LC-MS	NF6wPGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Moj2TWM2OD16LkO0PFU3KM7:TR?=	NXS3S293RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
RH-18	NVO1N2hRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkPyTWM2OD16LkO1NFQ3KM7:TR?=	M3LjdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
SW48	MofHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn7DTWM2OD16LkW5OFU{KM7:TR?=	Mn30QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
RD	M2i1[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV7JR\|UxRThwNUmzPVEh\|ryP	M3y4PVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
MS-1	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3vSb2lEPTB;OD62NVM5PyEQvF2=	MkLqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
ES6	M{XmR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MY\JR\|UxRThwN{OxNVkh\|ryP	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
TE-12	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYXJR\|UxRThwN{e1NFUh\|ryP	MoX1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
DBTRG-05MG	NXjoe3pWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXnJR\|UxRThwOUGyNVch\|ryP	NIPy[FI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
KINGS-1	Mn;JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH\nRoxKSzVyPUiuPVI6OzhizszN	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
HLE	NFnTe4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYW5WWN[UUN3ME24Mlk{Pzh3IN88US=>	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
MHH-NB-11	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mnv6TWM2OD17LkCxPFM6KM7:TR?=	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
U-87-MG	MnewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmrkTWM2OD17LkK0N\|IyKM7:TR?=	Mn2xQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
MN-60	M1X1UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXfJR\|UxRTlwMkS1OFIh\|ryP	NVW2cIg6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
SAS	NELR[\|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF7Xc\|BKSzVyPUmuNlU2QDFizszN	NWDSWXkzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
NCI-H446	MkfTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1PiXGlEPTB;OT6zOlEh\|ryP	NULVPGxpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
C-33-A	MkLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHHDZmFKSzVyPUmuOFM6QDhizszN	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
RXF393	M4XOW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnzSTWM2OD17LkS3NFAzKM7:TR?=	NFPIfGs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
CGTH-W-1	NXL2WpNtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXnJR\|UxRTlwNEmzPFQh\|ryP	NUDid2JNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
RCM-1	NVrrWHpZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGe3bWlKSzVyPUmuOlM5ODFizszN	M1[1SlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
SN12C	NFT3WJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUHufpk4UUN3ME25MlY2OzN6IN88US=>	NXf0UppwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
KLE	NGXYXolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NITWOZBKSzVyPUmuO\|AxODlizszN	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
EFO-21	MmjvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3jqUmlEPTB;OT63O\|M5OiEQvF2=	NV;GVYtoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
KYSE-70	NGPkW5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn7lTWM2OD17Lki4NFEyKM7:TR?=	M3ex[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
D-247MG	MmnWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2rMXWlEPTB;MUCuNFU3QCEQvF2=	MoLiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
MPP-89	NFLOdFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{SyRmlEPTB;MUCuNFk1PiEQvF2=	MmHaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
RVH-421	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYj6bFZbUUN3ME2xNE4yPTB3IN88US=>	M3jLb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
NCI-H460	NGDTdFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFnabmJKSzVyPUGwMlI5ODZizszN	NVnMSIZuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
NOMO-1	MmS4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoqzTWM2OD1zMD6zOVMzKM7:TR?=	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
DEL	MmXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXX4VYZvUUN3ME2xNE4{Pzl2IN88US=>	M4fMR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
HT55	NY\wb4xRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NE[0PG5KSzVyPUGwMlYzODVizszN	MmTpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
MC116	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGTJVpRKSzVyPUGwMlY3PTVizszN	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
BB30-HNC	NFHnb45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1WxWmlEPTB;MUCuOlY6KM7:TR?=	NF\GcGE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
DJM-1	NGTkfYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXLJR\|UxRTFyLk[5OFkh\|ryP	NFfIc4Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
ZR-75-30	NVPCVHRJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIfQO5ZKSzVyPUGwMlk1PDFizszN	M{nRfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
U-118-MG	NHvpWlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{eyWGlEPTB;MUCuPVg6PiEQvF2=	NF\1cnI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
MSTO-211H	M2\BSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGPrfVlKSzVyPUGxMlA4OTZizszN	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
SW837	NXnzbFdUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4i0[GlEPTB;MUGuNFk1QSEQvF2=	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
HuCCT1	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1;WZ2lEPTB;MUGuNVI5OSEQvF2=	NUfm[3RpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
RCC10RGB	MmnaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGm1VGxKSzVyPUGxMlE{PSEQvF2=	NILzS5Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
NMC-G1	M4nxWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUnJR\|UxRTFzLkG0PVMh\|ryP	M4nQeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
NCI-H650	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXjtc3VmUUN3ME2xNU4{Pzl2IN88US=>	NF;qTYc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
HEC-1	M4W4Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF33dXZKSzVyPUGxMlQ{OjhizszN	NUi0XnhJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
DU-4475	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHXzZplKSzVyPUGxMlc{QTNizszN	MnKxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
DSH1	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEjPd5lKSzVyPUGxMlc3ODZizszN	M4m5fVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
HCC1569	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2jZOGlEPTB;MUGuO\|Y4QCEQvF2=	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
HCC1187	NVH3Zm1LT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWnJR\|UxRTFzLki1PFgh\|ryP	NH74UXI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
EW-11	M3K5Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2PufmlEPTB;MUGuPVQ4PCEQvF2=	M1PQbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
LB2518-MEL	NIHzWIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MonUTWM2OD1zMj6wOVkh\|ryP	NWXoNZRQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
KALS-1	NIKxd3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1m5cmlEPTB;MUKuPFU2OyEQvF2=	M1rQelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
8505C	Mk\tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHHaNnFKSzVyPUGyMlg5PSEQvF2=	Ml35QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
SK-N-DZ	M4j0S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnvvTWM2OD1zMz6wOFU{KM7:TR?=	NEXSWZg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
CHP-134	M1j4PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVXJR\|UxRTF\|LkGxOVgh\|ryP	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
HCE-T	NF:wd2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmDlTWM2OD1zMz6yN\|Y1KM7:TR?=	Ml\BQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
LB-831-BLC	NEPtTGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWXJR\|UxRTF\|Lk[yOFYh\|ryP	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
OVCAR-4	M37Zemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX\JR\|UxRTF\|Lk[1NlQh\|ryP	M1PDOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
SW756	M2CzSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkXLTWM2OD1zMz63NlQ3KM7:TR?=	MlTJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
OCUB-M	NE\OTIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkPyTWM2OD1zMz64NVU3KM7:TR?=	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
SW982	NE\PU2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYXJR\|UxRTF\|LkiyO\|Yh\|ryP	MnrFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
DB	NGLmXW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV7JR\|UxRTF\|LkizPFQh\|ryP	MlPiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
H-EMC-SS	NYrwVJZET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXXOV29iUUN3ME2xN{46OTN7IN88US=>	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
VMRC-RCZ	Ml3sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVvZbpJUUUN3ME2xOE4xODF3IN88US=>	NWroVJFQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
CAKI-1	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX3GU3NNUUN3ME2xOE4xOTN{IN88US=>	NXfCXZB5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
GI-1	M2rMVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWfrTohnUUN3ME2xOE4xPjV6IN88US=>	MlLxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
Ca9-22	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHHpeolKSzVyPUG0MlYxPTRizszN	M3fyclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
TE-5	NHXWVFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mnq4TWM2OD1zND63NlA5KM7:TR?=	NIjiVo49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
EFO-27	NIrDc3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHixc49KSzVyPUG0Mlc3OjJizszN	NV3JR2J6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
CAL-72	MmHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2rD[WlEPTB;MUSuO\|c5OyEQvF2=	NIHlZWk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
GP5d	NVq5Z2xXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV\H[oVoUUN3ME2xOU4xPDd2IN88US=>	M3;LWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
CAS-1	NH;0PXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnTwTWM2OD1zNT6wOlYh\|ryP	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
A2058	M1rNb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH7mUnBKSzVyPUG1MlU3OzhizszN	MmWwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
PANC-08-13	Mmi2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmW0TWM2OD1zNT62PFU6KM7:TR?=	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
Detroit562	NX3iUHBPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2e1OWlEPTB;MUWuPVE{QSEQvF2=	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
PANC-10-05	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX3JR\|UxRTF4LkC4NlEh\|ryP	MoqzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
KOSC-2	NXrxcZUzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWnJR\|UxRTF4LkGxNlUh\|ryP	Mn7xQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
GT3TKB	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUHJR\|UxRTF4LkG5PFEh\|ryP	NVLSeJkyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
KM-H2	NY\JOnJoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1:4TWlEPTB;MU[uN\|Y1PiEQvF2=	Ml7VQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
LB771-HNC	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFHsSHdKSzVyPUG2MlQ1OjJizszN	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
SF268	Mof6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MonaTWM2OD1zNj60OVIh\|ryP	NWL0SnNpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
OE19	M33uWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1P4dWlEPTB;MU[uOVI1KM7:TR?=	NWXWfY5ERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
MLMA	M2LCfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUPJR\|UxRTF4LkW1O\|Eh\|ryP	MnzkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
MDA-MB-231	MkfRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUTBRmRtUUN3ME2xOk44OTN4IN88US=>	NFPDOXc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
TGW	MlW1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXH2PIxZUUN3ME2xOk45OTB{IN88US=>	NXXRdpVDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
MDA-MB-453	NXPrTppwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXXJR\|UxRTF5LkCwNFMh\|ryP	MoP0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
SNU-C2B	M4PsNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVvJR\|UxRTF5LkCyN\|ch\|ryP	M1zlRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
A427	Mo\FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmDZTWM2OD1zNz6yN\|M1KM7:TR?=	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
SK-MEL-2	NEPCWHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoO3TWM2OD1zNz6zNlE{KM7:TR?=	M3PVdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
KURAMOCHI	NYHiVJVUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEDpbY5KSzVyPUG3MlM5QTdizszN	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
IST-MEL1	NHTTXoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFrQTXlKSzVyPUG3MlkyQDJizszN	NV3YUIxZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
NCI-H1793	M4DRemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M33jb2lEPTB;MUiuNVU5OSEQvF2=	Ml3DQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
HCC1395	MmfOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M370S2lEPTB;MUiuOVYyOSEQvF2=	NXW4e2tPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
NUGC-3	MlXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoXrTWM2OD1zOD62OVg1KM7:TR?=	NUX6Um9XRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
BB65-RCC	Ml3WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVTi[Gg3UUN3ME2xPE43PjlizszN	MljzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
RMG-I	NGXT[nVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUOwXW5[UUN3ME2xPE44Ozh{IN88US=>	M4izblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
LS-513	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWPPSopUUUN3ME2xPE46OjJ6IN88US=>	NG\tdYo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
MFM-223	Mm\sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4[1TGlEPTB;MUmuNFcyPiEQvF2=	M3zTdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
NCI-H727	NX;TSIRYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHHMOXFKSzVyPUG5MlMzQTVizszN	MnrMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
KP-4	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXT1TYk5UUN3ME2xPU45PTNzIN88US=>	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
NB13	NULw[GU6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MljCTWM2OD1zOT64PFM6KM7:TR?=	NFPhV\|g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
UACC-893	NGHyV3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGrVVVdKSzVyPUG5Mlk4PTdizszN	NGD3bJk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
HT-1197	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmDiTWM2OD1{MD6yPVU5KM7:TR?=	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
NCI-H2029	M3fWb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoPQTWM2OD1{MD6zNlY3KM7:TR?=	Mn;XQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
GI-ME-N	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmrJTWM2OD1{MD6zN\|c{KM7:TR?=	M1;SfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
OVCAR-3	NVz5Tog4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnXNTWM2OD1{MD61PFIzKM7:TR?=	NGnzPZQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
HD-MY-Z	NIfNOplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYjG[XpRUUN3ME2yNU4{Pjl4IN88US=>	M1rr[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
NTERA-S-cl-D1	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX;JR\|UxRTJzLk[3NlIh\|ryP	M1eycVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
SCH	MoDDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX\JR\|UxRTJ{LkS5OkDPxE1?	NXvtSW92RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
KARPAS-299	MkTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NISxZVRKSzVyPUKzMlM5QDdizszN	MlPzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
NCI-H1650	NYXQV5pnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWTJR\|UxRTJ\|LkmyOFEh\|ryP	NUTwR5czRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
ACHN	NWTYVG95T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{S0NGlEPTB;MkSuOFY2PiEQvF2=	MmTSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
M059J	M2Cyemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX6zXHREUUN3ME2yOE42PjN2IN88US=>	NH7hcI09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
AM-38	MmDZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MW\JR\|UxRTJ3LkS4NUDPxE1?	Mln4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
KG-1	MnnIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3O4OWlEPTB;MkWuOVQ6PCEQvF2=	M1vadVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
COLO-824	M{flXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVzaNFdCUUN3ME2yOU42PTl7IN88US=>	M325WlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
NCI-H1155	NHjpTmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV3JR\|UxRTJ3LkW4OFch\|ryP	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
NCI-H441	M3;lXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1XGW2lEPTB;MkWuO\|Q3PSEQvF2=	MnKzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
J-RT3-T3-5	NYnMU\|BTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVHVbXM2UUN3ME2yOk4{ODJ5IN88US=>	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
JEG-3	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV3JR\|UxRTJ4Lk[4NFUh\|ryP	MoK1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
RKO	NVXRS5VsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NELtdWtKSzVyPUK2Mlc3OzJizszN	M12xPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
CAL-85-1	NYTW[HpYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH7lfGVKSzVyPUK3MlIyOThizszN	MoKwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
CAL-120	NYOzVHMyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml;lTWM2OD1{Nz62PVE1KM7:TR?=	MnPWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
NCI-H2452	NEHmT3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUXJR\|UxRTJ5Lke3NVYh\|ryP	M2PPNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
NCI-H1395	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVGxU3VJUUN3ME2yO{44QDN\|IN88US=>	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
KYSE-450	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mkf4TWM2OD1{Nz65PFYzKM7:TR?=	M{LtT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
S-117	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnT3TWM2OD1{OT6zPFU4KM7:TR?=	NVXHToMxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
SW13	NHXEbFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlPqTWM2OD1{OT64OVE6KM7:TR?=	NETvRYs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
ES3	NGW3fGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEXzV3lKSzVyPUOwMlM4OzNizszN	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
HCT-116	NVi1R\|kxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1PlTGlEPTB;M{CuOVU2PCEQvF2=	NIjFdVA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
NCI-H1693	MlznS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1HJS2lEPTB;M{CuOVk1OiEQvF2=	M1;ne\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
VM-CUB-1	NGG5b5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFHJVJpKSzVyPUOwMlY1OTNizszN	MnezQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
NCI-H2170	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnzUTWM2OD1\|MT61O\|g1KM7:TR?=	NWLWToRQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
ALL-PO	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGjJfYhKSzVyPUOxMlg1OjhizszN	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
NCI-H661	NIrCclhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3nkXmlEPTB;M{KuNFYzOyEQvF2=	NHLBWGs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
NCI-H2347	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1zaeGlEPTB;M{KuOFg{PyEQvF2=	NIO4fnQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
FTC-133	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2TYZmlEPTB;M{KuO\|A3KM7:TR?=	MlfyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
COLO-829	NF\KXXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVzpboQ5UUN3ME2zN{4{PDZ5IN88US=>	M{\aRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
GOTO	NV\rXpp{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4DH[2lEPTB;M{OuOVI2QCEQvF2=	NXfSSpRURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
YAPC	M2rPOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWf4NGJJUUN3ME2zN{45OTV7IN88US=>	NI\WWIY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
LCLC-103H	M1HrO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUntdIRVUUN3ME2zOE4yPjJ2IN88US=>	Mnr0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
SiHa	NVXkTJdNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1rPSWlEPTB;M{SuN\|gyPyEQvF2=	NYTZV3dtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
LK-2	NVrERmQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIC3R2VKSzVyPUO0MlU4ODhizszN	M1rnelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
KP-N-YS	NIWwVYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4nSTGlEPTB;M{SuO\|IxOiEQvF2=	MkPZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
NCI-SNU-1	Mlv1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1vmUGlEPTB;M{WuNVc6KM7:TR?=	M{G1O\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
KNS-81-FD	NGPzRnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{XlO2lEPTB;M{WuOlY{KM7:TR?=	NF[xSFc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
SCC-9	MmjFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXL4TnZMUUN3ME2zOk44OTR4IN88US=>	NUnxflhHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
SH-4	NF;yVINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWTJR\|UxRTN4LkezJO69VQ>?	NGPESGY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
HCC-1954	NGTFTJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXP0[IV3UUN3ME2zO{4zPzJ7IN88US=>	MmH5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
BALL-1	NGjufZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{D5T2lEPTB;M{euOVMyPiEQvF2=	NX3hbpd{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
BE-13	NYn4WlJzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFnDPXhKSzVyPUO3MlcxOThizszN	NITNS4I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
COLO-678	NWrFTWhNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml3lTWM2OD1\|Nz65OFM4KM7:TR?=	NVHMWVVRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
SK-MEL-3	M3nqN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYnJR\|UxRTN6LkKzPVch\|ryP	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
OAW-28	NHHUPW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1WwfmlEPTB;M{iuOlM6KM7:TR?=	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
CAMA-1	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmfpTWM2OD1\|OD65OlkyKM7:TR?=	NH\ob4I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
C2BBe1	Ml3mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWnPfIUzUUN3ME2zPU45OThizszN	M4TvblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
A3-KAW	NETqZ4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVXydot3UUN3ME20NE4{PjZzIN88US=>	M{LvS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
SK-MEL-24	NVHPT3l5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NW\zRWdHUUN3ME20NE42QTNzIN88US=>	MkTGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
KYSE-140	NIH5[IpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYfKNZJKUUN3ME20NE44OTZ3IN88US=>	MlHxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
MOLT-16	M4L5ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2PjcWlEPTB;NEGuNVU{PiEQvF2=	M{PqV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
CFPAC-1	NXvGXGltT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{nVUWlEPTB;NEKuOVIyOSEQvF2=	NGjKNXA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
NB14	NUK5WmxtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXPURoRJUUN3ME20Nk44ODJ5IN88US=>	M2DT[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
COLO-792	NHHxSVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mm[5TWM2OD12Mj64PVYyKM7:TR?=	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
RH-1	M3zOPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnvQTWM2OD12Mz60PFM3KM7:TR?=	NYO4NmR2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
NCI-H522	Ml7PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWjJR\|UxRTR2LkO1Olgh\|ryP	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
Ca-Ski	NXnw[Jd2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV7JR\|UxRTR2LkixNVQh\|ryP	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
KGN	NViwbIxDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1XMRmlEPTB;NEiuN\|A3OyEQvF2=	M17kdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
UACC-62	MonuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHKzRWVKSzVyPUS4MlQxPzJizszN	M4rtWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
NCI-H358	M1[1cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{TzW2lEPTB;NEmuN\|AyQCEQvF2=	MoXhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
LS-411N	NUm0R2Q3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn22TWM2OD12OT6zNVE5KM7:TR?=	MlLyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
IST-MES1	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEPvZ49KSzVyPUS5MlU3OjVizszN	MoO5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-AKT / AKT / p-FoxO3a / FoxO3a / PUMA; PubMed: 29137323 Oncotarget HCT116 cells were treated with 4μmol/L NVP-BKM120 or 4μmol/L Pictilisib for 24 hours. Indicated protein levels were analyzed by Western blotting. p-S6RP / S6RP; PubMed: 30042442 Cell Death Dis Western blot analysis of proteins as indicated in 4T1 cells treated with 1 µM GDC-0941 or vehicle for 24 h. Vinculin was used as a loading control. p-4EBP1 / 4EBP1; PubMed: 25857298 Oncotarget Cells were treated with 0.5 μM GDC-0941 for the indicated time course and then collected for Western blot analysis of p-4EBP1. p-LRP6 / LRP6; PubMed: 25857298 Oncotarget MDAMB-231, HCC1937 and MCF7 cells were treated with 0.5 µM GDC-0941 for 1 hr, and cell lysates were used for immunoblot analyses. p-PAK / PAK1 / p-CRAF / RAF / p-MEK / MEK / p-ERK / ERK; PubMed: 24327733 Proc Natl Acad Sci U S A Cells were treated with 1 μM GDC-0941 for the indicated times, and lysates were probed with the indicated antibodies. Independent experiments were performed at least three times, and a representative result is shown.	29137323 30042442 25857298 24327733
Immunofluorescence	p65; PubMed: 30042442 Cell Death Dis Representative images of immunofluorescent staining of p65 cellular localization in 4T1 cells treated with 1 µM GDC-0941 or vehicle for 24 h. 4T1 cells were cultured alone or co-cultured with RAW264.7 macrophages. Representative images of three independent experiments are shown. beta-catenin; PubMed: 25857298 Oncotarget Cells were seeded on coverslips the day before the experiment and treated with 0.5 µM GDC-0941 for 18 hr. The immunofluorescence (IF) of beta-catenin is indicated as red fluorescence, and double staining with DAPI is blue. Magnification: 400 X for the left three panels. The right panel shows enlarged images from the white squares.	30042442 25857298
Growth inhibition assay	Cell viability; PubMed: 27117832 J Thorac Oncol The viability of the indicated cells treated with increasing concentrations of GDC-0941 (ranging from 70nM to 20 μM) for 72 hours, determined by CellTiter Glo Viability assay. The IC50 concentrations were calculated using GraphPad Prism program. The assay was performed in triplicate, and the error bars represent standard deviations.	27117832

In vivo

GDC-0941 shows limited microsomal metabolism, resulting in 78% oral bioavailability ^[5]. Administration of GDC-0941 at 75 mg/kg/day displays significant inhibitory effect against established human U87MG glioblastoma xenografts in female NCr athymic mice, with tumor growth inhibition of 83%. ^[1] Oral administration of GDC-0941 at 150 mg/kg/day inhibits the growth of HER2-amplified, trastuzumab-resistant MDA-MB-361.1 xenografts in mice, and significantly delays the tumor progression, in association with potent induced apoptosis in tumors. ^[2] GDC-0941 (75 mg/kg/day) treatment for 2 weeks induces ~40% reduction in tumor volume of spontaneous B-cell follicular lymphomas developed in PTEN+/-LKB1+/hypo mice, accompanied by ablation of phosphorylation of Akt, S6K and SGK (serum and glucocorticoid protein kinase) protein kinases. ^[4]

Protocol

Kinase Assay: ^[1]	- Collapse Scintillation proximity assay: Recombinant human PI3Kα, PI3Kβ, and PI3Kδ are coexpressed in a Sf9 baculovirus system with the p85α regulatory subunit and purified as GST-fusion proteins using affinity chromatography on glutathione-sepharose. Recombinant human PI3Kγ is expressed as monomeric GST-fusions and purified similarly. GDC-0941 is dissolved in DMSO and added to 20 mM Tris-HCl (pH 7.5) containing 200 μg yttrium silicate (Ysi) polylysine SPA beads, 4 mM MgCl₂, 1 mM dithiothreitol (DTT), 1 μM ATP, 0.125 μCi [γ-³³P]-ATP, and 4% (v/v) DMSO in a total volume of 50 μL. The recombinant GST-fusion of PI3Kα (5 ng), PI3Kβ (5 ng), PI3Kδ (5 ng), or PI3Kγ (5 ng) is added to the assay mixture to initiate the kinase reaction. After incubation for 1 hour at room temperature, the kinase reaction is terminated with 150 μL PBS. The mixture is then centrifuged for 2 minutes at 2000 rpm and read using a Wallac Microbeta counter. The reported IC50 values are calculated using a sigmoidal, dose-response curve fit in MDL Assay Explorer.
Cell Research: ^[2]	- Collapse Cell lines: SKBR-3, BT474-M1, AU-565, HCC-1419, ZR75-30, KPL-4, JIMT-1, BT474-EEI, HCC-1954, MCF-7, CALU-3, SKOV-3, and MKN-7 cells Concentrations: Dissolved in DMSO, final concentrations ~10 μM Incubation Time: 48 and 72 hours Method: Cells are exposed to various concentrations of GDC-0941 for 48, and 72 hours. Proliferation/viability of cells is detected by using the CellTiter-Glo Luminescent Cell Viability Assay. The pAkt (Ser473), cleaved caspase-3, and cleaved PARP are analyzed by western blot. The Caspase-Glo 3/7 assay and the Cell Death Detection ELISA^plus assay are used to detect caspase 3/7 activity, and apoptosis, respectively. (Only for Reference)
Animal Research: ^[2]	- Collapse Animal Models: NCR nude mice implanted with MDA-MB-361.1 cells, and SCID, C.B-17/IcrHsd-Prkdc^scid mice implanted subcutaneously with BT474-M1 cells Dosages: ~150 mg/kg/day Administration: Oral gavage (Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	44 mg/mL (85.66 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+30% PEG 300+5% Tween 80+ddH2O For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Pictilisib (GDC-0941) SDF

Molecular Weight	513.64
Formula	C₂₃H₂₇N₇O₃S₂
CAS No.	957054-30-7
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	RG7321
Smiles	CS(=O)(=O)N1CCN(CC1)CC2=CC3=C(S2)C(=NC(=N3)C4=C5C=NNC5=CC=C4)N6CCOCC6

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2020-01-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT02092831	Completed	Drug: GDC-0941	Healthy Volunteer	Genentech Inc.	April 2014	Phase 1
NCT01740336	Completed	Drug: GDC-0941\|Drug: Placebo\|Drug: Paclitaxel	Breast Cancer	Genentech Inc.	February 6 2013	Phase 2
NCT01474668	Completed	Drug: GDC-0941	Healthy Volunteer	Genentech Inc.	October 2011	Phase 1
NCT01240226	Completed	Drug: GDC-0941\|Drug: ketoconazole	Healthy Volunteer	Genentech Inc.	November 2010	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Pan PI3K Inhibitor

LY294002 : Pan-PI3Kα/δ/β inhibitor, IC50=0.5 μM/0.57 μM/0.97 μM.
Most Potent PI3K Inhibitor

Duvelisib (IPI-145, INK1197) : PI3K δ, IC50=1 nM.
FDA-approved PI3K Inhibitor

CAL-101 (Idelalisib, GS-1101) : Approved by FDA for Relapsed Chronic Lymphocytic Leukemia, Follicular Lymphoma and Small Lymphocytic Lymphoma.
Newest PI3K Inhibitor

GSK2636771 : Potent, orally bioavailable, PI3Kβ-selective inhibitor, sensitive to PTEN null cell lines.

Related PI3K Products

Taselisib (GDC 0032) ^New

Taselisib (GDC 0032, RG7604) is a potent, next-generation β isoform-sparing PI3K inhibitor targeting PI3Kα/δ/γ with K_i of 0.29 nM/0.12 nM/0.97nM, >10 fold selective over PI3Kβ.

Features:A beta isoform-sparing PI3K inhibitor.
Pilaralisib (XL147) ^New

Pilaralisib (XL147) is a selective and reversible class I PI3K inhibitor for PI3Kα/δ/γ with IC50 of 39 nM/36 nM/23 nM in cell-free assays, less potent to PI3Kβ. Phase 1/2.
GNE-317 ^New

GNE-317 is a potent, brain-penetrant PI3K inhibitor.
LY294002

LY294002 (SF 1101, NSC 697286) is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation. It not only binds to class I PI3Ks and other PI3K-related kinases, but also to novel targets seemingly unrelated to the PI3K family. LY294002 also inhibits CK2 with IC50 of 98 nM. LY294002 is a non-specific DNA-PKcs inhibitor and activates autophagy and apoptosis.
3-Methyladenine (3-MA)

3-Methyladenine (3-MA, NSC 66389) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM in HeLa cells; blocks class I PI3K consistently, whereas suppression of class III PI3K is transient, and also blocks autophagosome formation. 3-Methyladenine (3-MA) is successfully used to suppress mitophagy. Solutions of 3-MA are best fresh-prepared by heating.
Idelalisib (CAL-101, GS-1101)

Idelalisib (CAL-101, GS-1101) is a selective p110δ inhibitor with IC50 of 2.5 nM in cell-free assays; shown to have 40- to 300-fold greater selectivity for p110δ than p110α/β/γ, and 400- to 4000-fold more selectivity to p110δ than C2β, hVPS34, DNA-PK and mTOR. Idelalisib also stimulates autophagy.
Wortmannin

Wortmannin (KY 12420) is the first described PI3K inhibitor with IC50 of 3 nM in a cell-free assay, with little selectivity within the PI3K family. Wortmannin blocks autophagosome formation and potently inhibits DNA-PK/ATM with IC50 of 16 nM and 150 nM in cell-free assays. Wortmannin also inhibits PLK1 activity.
Dactolisib (BEZ235)

Dactolisib (BEZ235, NVP-BEZ235) is a dual ATP-competitive PI3K and mTOR inhibitor for p110α/γ/δ/β and mTOR(p70S6K) with IC50 of 4 nM /5 nM /7 nM /75 nM /6 nM in cell-free assays, respectively. Inhibits ATR with IC50 of 21 nM in 3T3^TopBP1-ER cell. Dactolisib induces autophagy and suppresses HIV-1 replication. Phase 2.
Buparlisib (BKM120)

Buparlisib (BKM120, NVP-BKM120) is a selective PI3K inhibitor of p110α/β/δ/γ with IC50 of 52 nM/166 nM/116 nM/262 nM in cell-free assays, respectively. Reduced potency against VPS34, mTOR, DNAPK, with little activity to PI4Kβ. Buparlisib induces apoptosis. Phase 2.
Alpelisib (BYL719)

Alpelisib (BYL719) is a potent and selective PI3Kα inhibitor with IC50 of 5 nM in a cell-free assay, and minimal effect on PI3Kβ/γ/δ. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Pictilisib (GDC-0941)